Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Plaetzer K, Krammer B, Berlanda J, Berr F, Kiesslich T (2009) Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med Sci 24(2):259–268. https://doi.org/10.1007/s10103-008-0539-1

doi: 10.1007/s10103-008-0539-1 pubmed: 18247081

Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61(4):250–281. https://doi.org/10.3322/caac.20114

doi: 10.3322/caac.20114 pubmed: 21617154 pmcid: 3209659

Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6(7):535–545. https://doi.org/10.1038/nrc1894

doi: 10.1038/nrc1894 pubmed: 16794636 pmcid: 2933780

Falk-Mahapatra R, Gollnick SO (2020) Photodynamic Therapy and Immunity: An Update. Photochem Photobiol, 96: 550–559. https://doi.org/10.1111/php.13253

Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M (2015) Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev 34(4):643–690. https://doi.org/10.1007/s10555-015-9588-7

doi: 10.1007/s10555-015-9588-7 pubmed: 26516076 pmcid: 4661210

Weijer R, Broekgaarden M, van Golen RF, Bulle E, Nieuwenhuis E, Jongejan A, Moerland PD, van Kampen AHC, van Gulik TM, Heger M (2015) Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. BMC Cancer 15(1):1014. https://doi.org/10.1186/s12885-015-1994-2

doi: 10.1186/s12885-015-1994-2 pubmed: 26705830 pmcid: 4691291

Ferrario A, Gomer CJ (2010) Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett 289(2):188–194. https://doi.org/10.1016/j.canlet.2009.08.015

doi: 10.1016/j.canlet.2009.08.015 pubmed: 19733005

Broekgaarden M, Weijer R, Krekorian M, van den Ijssel B, Kos M, Alles LK, van Wijk AC, Bikadi Z, Hazai E, van Gulik TM, Heger M (2016) Inhibition of hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic tumor cells to photodynamic therapy with zinc phthalocyanine-encapsulating cationic liposomes. Nano Res 9(6):1639–1662. https://doi.org/10.1007/s12274-016-1059-0

doi: 10.1007/s12274-016-1059-0

Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M (2016) Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget 7(3):3341–3356. https://doi.org/10.18632/oncotarget.6490

doi: 10.18632/oncotarget.6490 pubmed: 26657503

Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12(19):853–859. https://doi.org/10.1016/j.drudis.2007.08.006

doi: 10.1016/j.drudis.2007.08.006 pubmed: 17933687

Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ (2009) An integrative genomics approach identifies hypoxia inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 37(14):4587–4602. https://doi.org/10.1093/nar/gkp425

doi: 10.1093/nar/gkp425 pubmed: 19491311 pmcid: 2724271

Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR (2011) High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117(23):e207–e217. https://doi.org/10.1182/blood-2010-10-314427

doi: 10.1182/blood-2010-10-314427 pubmed: 21447827 pmcid: 3374576

Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4):207–214. https://doi.org/10.1016/j.tips.2012.01.005

doi: 10.1016/j.tips.2012.01.005 pubmed: 22398146 pmcid: 3437546

Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L (1997) Activation of hypoxia-inducible factor 1α: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A 94(11):5667–5672. https://doi.org/10.1073/pnas.94.11.5667

doi: 10.1073/pnas.94.11.5667 pubmed: 9159130 pmcid: 20836

Ke Q, Costa M (2006) Hypoxia-inducible Factor-1 (HIF-1). Mol Pharmacol 70(5):1469–1480. https://doi.org/10.1124/mol.106.027029

doi: 10.1124/mol.106.027029 pubmed: 16887934

Buckley DL, Van Molle I, Gareiss PC, Tae HS, Michel J, Noblin DJ, Jorgensen WL, Ciulli A, Crews CM (2012) Targeting the von Hippel–Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc 134(10):4465–4468. https://doi.org/10.1021/ja209924v

doi: 10.1021/ja209924v pubmed: 22369643 pmcid: 3448299

Weidemann A, Johnson RS (2008) Biology of HIF-1α. Cell Death Differ 15:621. https://doi.org/10.1038/cdd.2008.12

doi: 10.1038/cdd.2008.12 pubmed: 18259201

Yasumoto K-i, Kowata Y, Yoshida A, Torii S, Sogawa K (2009) Role of the intracellular localization of HIF-prolyl hydroxylases. Biochim Biophys Acta 1793(5):792–797. https://doi.org/10.1016/j.bbamcr.2009.01.014

doi: 10.1016/j.bbamcr.2009.01.014 pubmed: 19339211

Krek W (2000) VHL takes HIF’s breath away. Nat Cell Biol 2:E121. https://doi.org/10.1038/35017129

doi: 10.1038/35017129 pubmed: 10878820

Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML (2002) Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295(5556):858–861. https://doi.org/10.1126/science.1068592

doi: 10.1126/science.1068592 pubmed: 11823643

Lau KW, Tian YM, Raval RR, Ratcliffe PJ, Pugh CW (2007) Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer 96:1284. https://doi.org/10.1038/sj.bjc.6603675 . https://www.nature.com/articles/6603675#supplementary-information

doi: 10.1038/sj.bjc.6603675 pubmed: 17387348 pmcid: 2360163

Rey S, Semenza GL (2010) Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 86(2):236–242. https://doi.org/10.1093/cvr/cvq045

doi: 10.1093/cvr/cvq045 pubmed: 20164116 pmcid: 2856192

Yeo E-J, Ryu J-H, Cho Y-S, Chun Y-S, Huang LE, Kim M-S, Park J-W (2006) Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood 107(3):916–923. https://doi.org/10.1182/blood-2005-06-2564

doi: 10.1182/blood-2005-06-2564 pubmed: 16189267

Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ, Schofield CJ (2003) Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J Biol Chem 278(3):1802–1806. https://doi.org/10.1074/jbc.C200644200

doi: 10.1074/jbc.C200644200 pubmed: 12446723

Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A (2005) Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 280(51):41928–41939. https://doi.org/10.1074/jbc.M508718200

doi: 10.1074/jbc.M508718200 pubmed: 16223732

Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343. https://doi.org/10.1038/nrm1366 . https://www.nature.com/articles/nrm1366#supplementary-information

doi: 10.1038/nrm1366 pubmed: 15122348

Patten DA, Lafleur VN, Robitaille GA, Chan DA, Giaccia AJ, Richard DE, Gutkind JS (2010) Hypoxia-inducible Factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species. Mol Biol Cell 21(18):3247–3257. https://doi.org/10.1091/mbc.e10-01-0025

doi: 10.1091/mbc.e10-01-0025 pubmed: 20660157 pmcid: 2938389

Bleier L, Dröse S (2013) Superoxide generation by complex III: from mechanistic rationales to functional consequences. Biochim Biophys Acta 1827(11):1320–1331. https://doi.org/10.1016/j.bbabio.2012.12.002

doi: 10.1016/j.bbabio.2012.12.002 pubmed: 23269318

Calvani M, Comito G, Giannoni E, Chiarugi P (2012) Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species. PLoS One 7(10):e38388. https://doi.org/10.1371/journal.pone.0038388

doi: 10.1371/journal.pone.0038388 pubmed: 23144690 pmcid: 3483303

Juhasz A, Markel S, Gaur S, Liu H, Lu J, Jiang G, Wu X, Antony S, Wu Y, Melillo G, Meitzler JL, Haines DC, Butcher D, Roy K, Doroshow JH (2017) NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction. J Biol Chem 292(19):7866–7887. https://doi.org/10.1074/jbc.M116.768283

doi: 10.1074/jbc.M116.768283 pubmed: 28330872 pmcid: 5427267

Taylor CT, Cummins EP (2009) The role of NF-κB in hypoxia-induced gene expression. Ann N Y Acad Sci 1177(1):178–184. https://doi.org/10.1111/j.1749-6632.2009.05024.x

doi: 10.1111/j.1749-6632.2009.05024.x pubmed: 19845620

Beinke S, Ley SC (2004) Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 382(2):393–409. https://doi.org/10.1042/bj20040544

doi: 10.1042/bj20040544 pubmed: 15214841 pmcid: 1133795

Jiang Y, Zhu Y, Wang X, Gong J, Hu C, Guo B, Zhu B, Li Y (2015) Temporal regulation of HIF-1 and NF-kappaB in hypoxic hepatocarcinoma cells. Oncotarget 6(11):9409–9419. https://doi.org/10.18632/oncotarget.3352

doi: 10.18632/oncotarget.3352 pubmed: 25823824 pmcid: 4496226

Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS (2002) NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 30(12):1419–1427

doi: 10.1016/S0301-472X(02)00934-7 pubmed: 12482504

Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59(1):15–26. https://doi.org/10.1016/j.critrevonc.2005.12.003

doi: 10.1016/j.critrevonc.2005.12.003 pubmed: 16716598

Land SC, Tee AR (2007) Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282(28):20534–20543. https://doi.org/10.1074/jbc.M611782200

doi: 10.1074/jbc.M611782200 pubmed: 17502379

Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE (2014) PTEN function: the long and the short of it. Trends Biochem Sci 39(4):183–190. https://doi.org/10.1016/j.tibs.2014.02.006

doi: 10.1016/j.tibs.2014.02.006 pubmed: 24656806 pmcid: 4043120

Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17(17):5001–5014. https://doi.org/10.1093/emboj/17.17.5001

doi: 10.1093/emboj/17.17.5001 pubmed: 9724636 pmcid: 1170828

Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP (2000) p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 14(18):2358–2365

doi: 10.1101/gad.827300 pubmed: 10995391 pmcid: 316930

Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM (2004) p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Investig Dermatol 122(5):1284–1292. https://doi.org/10.1111/j.0022-202X.2004.22501.x

doi: 10.1111/j.0022-202X.2004.22501.x pubmed: 15140233

Fatyol K, Szalay AA (2001) The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription. J Biol Chem 276(30):28421–28429. https://doi.org/10.1074/jbc.M102847200

doi: 10.1074/jbc.M102847200 pubmed: 11382768

Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A (2002) Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem 277(45):42919–42925. https://doi.org/10.1074/jbc.M206141200

doi: 10.1074/jbc.M206141200 pubmed: 12200433

Lee H-Y, Lee T, Lee N, Yang EG, Lee C, Lee J, Moon E-Y, Ha J, Park H (2011) Src activates HIF-1α not through direct phosphorylation of HIF-1α-specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway. Carcinogenesis 32(5):703–712. https://doi.org/10.1093/carcin/bgr034

doi: 10.1093/carcin/bgr034 pubmed: 21335603

Brown JM (2014) Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy. Br J Radiol 87(1035):20130686. https://doi.org/10.1259/bjr.20130686

doi: 10.1259/bjr.20130686 pubmed: 24338942 pmcid: 4064599

Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93(11):1074–1081. https://doi.org/10.1161/01.res.0000102937.50486.1b

doi: 10.1161/01.res.0000102937.50486.1b pubmed: 14576200

Li N, Li Y, Li Z, Huang C, Yang Y, Lang M, Cao J, Jiang W, Xu Y, Dong J, Ren H (2016) Hypoxia inducible factor 1 (HIF-1) recruits macrophage to activate pancreatic stellate cells in pancreatic ductal adenocarcinoma. Int J Mol Sci 17(6):799. https://doi.org/10.3390/ijms17060799

doi: 10.3390/ijms17060799 pmcid: 4926333

McMurtry S (2013) Angiogenesis, arteriogenesis, and mitochondrial dysfunction. https://doi.org/10.1007/978-1-4614-5930-9_15

Yu JL, Rak JW (2003) Host microenvironment in breast cancer development inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 5(2):83. https://doi.org/10.1186/bcr573

doi: 10.1186/bcr573 pubmed: 12631386 pmcid: 154151

Urry LA, Cain ML, Wasserman SA, Minorsky PV, Reece JB (2017) Campbell biology

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. https://doi.org/10.1126/science.1160809

doi: 10.1126/science.1160809 pubmed: 19460998 pmcid: 2849637

Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL (1998) Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149–162

doi: 10.1101/gad.12.2.149 pubmed: 9436976 pmcid: 316445

Osada-Oka M, Hashiba Y, Akiba S, Imaoka S, Sato T (2010) Glucose is necessary for stabilization of hypoxia-inducible factor-1α under hypoxia: contribution of the pentose phosphate pathway to this stabilization. FEBS Lett 584(14):3073–3079. https://doi.org/10.1016/j.febslet.2010.05.046

doi: 10.1016/j.febslet.2010.05.046 pubmed: 20621833

Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276(46):43407–43412. https://doi.org/10.1074/jbc.M108181200

doi: 10.1074/jbc.M108181200 pubmed: 11557773

Minchenko O, Opentanova I, Caro J (2003) Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1–4) expression in vivo. FEBS Lett 554(3):264–270. https://doi.org/10.1016/S0014-5793(03)01179-7

doi: 10.1016/S0014-5793(03)01179-7 pubmed: 14623077

Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403. https://doi.org/10.1038/386403a0

doi: 10.1038/386403a0 pubmed: 9121557

Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269(38):23757–23763

doi: 10.1016/S0021-9258(17)31580-6 pubmed: 8089148

Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23(24):9361–9374. https://doi.org/10.1128/mcb.23.24.9361-9374.2003

doi: 10.1128/mcb.23.24.9361-9374.2003 pubmed: 14645546 pmcid: 309606

Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705. https://doi.org/10.1038/nrc2468

doi: 10.1038/nrc2468 pubmed: 19143055

Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281(14):9030–9037. https://doi.org/10.1074/jbc.M511397200

doi: 10.1074/jbc.M511397200 pubmed: 16452478

Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49(16):4373–4384

pubmed: 2545340

Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129(1):111–122. https://doi.org/10.1016/j.cell.2007.01.047

doi: 10.1016/j.cell.2007.01.047 pubmed: 17418790

Sutphin PD, Giaccia AJ, Chan DA (2007) Energy regulation: HIF MXIes it up with the C-MYC powerhouse. Dev Cell 12(6):845–846. https://doi.org/10.1016/j.devcel.2007.05.006

doi: 10.1016/j.devcel.2007.05.006 pubmed: 17543856

Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS (2005) Mxi1 is induced by hypoxia in a HIF-1–dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 4(11):1285–1294. https://doi.org/10.4161/cbt.4.11.2299

doi: 10.4161/cbt.4.11.2299 pubmed: 16319523

Lee TC, Ziff EB (1999) Mxi1 is a repressor of the c-Myc promoter and reverses activation by USF. J Biol Chem 274(2):595–606

doi: 10.1074/jbc.274.2.595 pubmed: 9872993

Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang Chi V, Semenza GL (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11(5):407–420. https://doi.org/10.1016/j.ccr.2007.04.001

doi: 10.1016/j.ccr.2007.04.001 pubmed: 17482131

LaGory EL, Wu C, Taniguchi Cullen M, Cornelia Ding C-K, Chi J-T, von Eyben R, Scott David A, Richardson Adam D, Giaccia Amato J (2015) Suppression of PGC-1α is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep 12(1):116–127. https://doi.org/10.1016/j.celrep.2015.06.006

doi: 10.1016/j.celrep.2015.06.006 pubmed: 26119730 pmcid: 4518559

Sweeney C, Murphy M, Kubelka M, Ravnik SE, Hawkins CF, Wolgemuth DJ, Carrington M (1996) A distinct cyclin a is expressed in germ cells in the mouse. Development 122(1):53–64

doi: 10.1242/dev.122.1.53 pubmed: 8565853

Nguyen TB, Manova K, Capodieci P, Lindon C, Bottega S, Wang XY, Refik-Rogers J, Pines J, Wolgemuth DJ, Koff A (2002) Characterization and expression of mammalian cyclin b3, a prepachytene meiotic cyclin. J Biol Chem 277(44):41960–41969. https://doi.org/10.1074/jbc.M203951200

doi: 10.1074/jbc.M203951200 pubmed: 12185076

Bretones G, Delgado MD, León J (2015) Myc and cell cycle control. Biochim Biophys Acta 1849(5):506–516. https://doi.org/10.1016/j.bbagrm.2014.03.013

doi: 10.1016/j.bbagrm.2014.03.013 pubmed: 24704206

Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6(9):3614–3620

pubmed: 10999753

Hubbi ME, Semenza GL (2015) Regulation of cell proliferation by hypoxia-inducible factors. Am J Physiol Cell Physiol 309(12):C775–C782. https://doi.org/10.1152/ajpcell.00279.2015

doi: 10.1152/ajpcell.00279.2015 pubmed: 26491052 pmcid: 4683214

Montagnoli A, Moll J, Colotta F (2010) Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 16(18):4503–4508. https://doi.org/10.1158/1078-0432.ccr-10-0185

doi: 10.1158/1078-0432.ccr-10-0185 pubmed: 20647475

Pucci B, Kasten M, Giordano A (2000) Cell cycle and apoptosis. Neoplasia (New York, NY) 2(4):291–299. https://doi.org/10.1038/sj.neo.7900101

doi: 10.1038/sj.neo.7900101

Masai H, Taniyama C, Ogino K, Matsui E, Kakusho N, Matsumoto S, Kim JM, Ishii A, Tanaka T, Kobayashi T, Tamai K, Ohtani K, Arai K (2006) Phosphorylation of MCM4 by Cdc7 kinase facilitates its interaction with Cdc45 on the chromatin. J Biol Chem 281(51):39249–39261. https://doi.org/10.1074/jbc.M608935200

doi: 10.1074/jbc.M608935200 pubmed: 17046832

Hamilton E, Infante JR (2016) Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 45:129–138. https://doi.org/10.1016/j.ctrv.2016.03.002

doi: 10.1016/j.ctrv.2016.03.002 pubmed: 27017286

Joaquin M, Gubern A, Posas F (2012) A novel G1 checkpoint mediated by the p57 CDK inhibitor and p38 SAPK promotes cell survival upon stress. Cell Cycle 11(18):3339–3340. https://doi.org/10.4161/cc.21840

doi: 10.4161/cc.21840 pubmed: 22918239 pmcid: 3466532

Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS (2003) Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23(1):359–369. https://doi.org/10.1128/mcb.23.1.359-369.2003

doi: 10.1128/mcb.23.1.359-369.2003 pubmed: 12482987 pmcid: 140666

Iida T, Mine S, Fujimoto H, Suzuki K, Minami Y, Tanaka Y (2002) Hypoxia-inducible factor-1α induces cell cycle arrest of endothelial cells. Genes Cells 7(2):143–149. https://doi.org/10.1046/j.1356-9597.2001.00512.x

doi: 10.1046/j.1356-9597.2001.00512.x pubmed: 11895478

Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E (1998) Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485. https://doi.org/10.1038/28867 . https://www.nature.com/articles/28867#supplementary-information

doi: 10.1038/28867 pubmed: 9697772

Obacz J, Pastorekova S, Vojtesek B, Hrstka R (2013) Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer 12(1):93. https://doi.org/10.1186/1476-4598-12-93

doi: 10.1186/1476-4598-12-93 pubmed: 23945296 pmcid: 3844392

Ortmann B, Druker J, Rocha S (2014) Cell cycle progression in response to oxygen levels. Cell Mol Life Sci 71(18):3569–3582. https://doi.org/10.1007/s00018-014-1645-9

doi: 10.1007/s00018-014-1645-9 pubmed: 24858415 pmcid: 4143607

Miller M, Shirole N, Tian R, Pal D, Sordella R (2016) The evolution of TP53 mutations: from loss-of-function to separation-of-function mutants. J Cancer Biol Res 4(4):1091

pubmed: 28191499 pmcid: 5298884

Hubbi ME, Kshitiz GDM, Rey S, Wong CC, Luo W, Kim D-H, Dang CV, Levchenko A, Semenza GL (2013) A nontranscriptional role for HIF-1α as a direct inhibitor of DNA replication. Sci Signal 6(262):ra10–ra10. https://doi.org/10.1126/scisignal.2003417

doi: 10.1126/scisignal.2003417 pubmed: 23405012 pmcid: 4124626

Moser Sandra C, Bensaddek D, Ortmann B, Maure J-F, Mudie S, Blow JJ, Lamond Angus I, Swedlow Jason R, Rocha S (2013) PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the Centrosomal protein Cep192. Dev Cell 26(4):381–392. https://doi.org/10.1016/j.devcel.2013.06.014

doi: 10.1016/j.devcel.2013.06.014 pubmed: 23932902 pmcid: 3757158

Ortmann B, Bensaddek D, Carvalhal S, Moser SC, Mudie S, Griffis ER, Swedlow JR, Lamond AI, Rocha S (2016) CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cells. J Cell Sci 129(1):191–205. https://doi.org/10.1242/jcs.179911

doi: 10.1242/jcs.179911 pubmed: 26644182 pmcid: 4732302

Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57(10):1009–1014. https://doi.org/10.1136/jcp.2003.015032

doi: 10.1136/jcp.2003.015032 pubmed: 15452150 pmcid: 1770458

van de Schepop HA, de Jong JS, van Diest PJ, Baak JP (1996) Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathol 49(4):M214–M217

doi: 10.1136/mp.49.4.M214 pubmed: 16696077 pmcid: 408061

Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516. https://doi.org/10.1080/01926230701320337

doi: 10.1080/01926230701320337 pubmed: 17562483 pmcid: 2117903

Ichim G, Tait SWG (2016) A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer 16:539. https://doi.org/10.1038/nrc.2016.58

doi: 10.1038/nrc.2016.58 pubmed: 27364482

Thorburn A (2007) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2(6):461–465. https://doi.org/10.1097/JTO.0b013e31805fea64

doi: 10.1097/JTO.0b013e31805fea64 pubmed: 17545839

Happo L, Strasser A, Cory S (2012) BH3-only proteins in apoptosis at a glance. J Cell Sci 125(Pt 5):1081–1087. https://doi.org/10.1242/jcs.090514

doi: 10.1242/jcs.090514 pubmed: 22492984 pmcid: 3324577

Findley HW, Gu L, Yeager AM, Zhou M (1997) Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89(8):2986–2993

doi: 10.1182/blood.V89.8.2986 pubmed: 9108419

Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L (2003) PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A 100(4):1931–1936. https://doi.org/10.1073/pnas.2627984100

doi: 10.1073/pnas.2627984100 pubmed: 12574499 pmcid: 149936

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ (2011) The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med (Cambridge, Mass) 17(11–12):1262–1274. https://doi.org/10.2119/molmed.2011.00176

doi: 10.2119/molmed.2011.00176

Sasabe E, Tatemoto Y, Li D, Yamamoto T, Osaki T (2005) Mechanism of HIF-1α-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96(7):394–402. https://doi.org/10.1111/j.1349-7006.2005.00065.x

doi: 10.1111/j.1349-7006.2005.00065.x pubmed: 16053510

An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392(6674):405–408. https://doi.org/10.1038/32925

doi: 10.1038/32925 pubmed: 9537326

Hansson LO, Friedler A, Freund S, Rudiger S, Fersht AR (2002) Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A 99(16):10305–10309. https://doi.org/10.1073/pnas.122347199

doi: 10.1073/pnas.122347199 pubmed: 12124396 pmcid: 124909

Parandavar E, Yazdanparast R (2017) Differential impact of various reactive oxygen species (ROS) on HIF-1alpha/p53 direct interaction in SK-N-MC neuroblastoma cells. Cell Biosci 7:52. https://doi.org/10.1186/s13578-017-0180-4

doi: 10.1186/s13578-017-0180-4 pubmed: 29051813 pmcid: 5633900

Burton TR, Gibson SB (2009) The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ 16:515. https://doi.org/10.1038/cdd.2008.185

doi: 10.1038/cdd.2008.185 pubmed: 19136941

Kubli Dieter A, Ycaza John E, Gustafsson Åsa B (2007) Bnip3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem J 405(3):407–415. https://doi.org/10.1042/bj20070319

doi: 10.1042/bj20070319 pubmed: 17447897 pmcid: 2267317

Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL (2001) HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61(18):6669–6673

pubmed: 11559532

Liu KE, Frazier WA (2015) Phosphorylation of the BNIP3 C-terminus inhibits mitochondrial damage and cell death without blocking autophagy. PLoS One 10(6):e0129667. https://doi.org/10.1371/journal.pone.0129667

doi: 10.1371/journal.pone.0129667 pubmed: 26102349 pmcid: 4477977

Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA, Gibson SB (2003) BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22:4734. https://doi.org/10.1038/sj.onc.1206666

doi: 10.1038/sj.onc.1206666 pubmed: 12879018

Liu X-H, Yu EZ, Li Y-Y, Kagan E (2006) HIF-1α has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J Cell Biochem 97(4):755–765. https://doi.org/10.1002/jcb.20683

doi: 10.1002/jcb.20683 pubmed: 16229017

Sendoel A, Hengartner MO (2014) Apoptotic Cell Death Under Hypoxia. Phys Ther 29(3):168–176. https://doi.org/10.1152/physiol.00016.2013

doi: 10.1152/physiol.00016.2013

Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M, Michiels C (2005) Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280(10):9336–9344. https://doi.org/10.1074/jbc.M411858200

doi: 10.1074/jbc.M411858200 pubmed: 15611089

Kilic M, Kasperczyk H, Fulda S, Debatin KM (2006) Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26:2027. https://doi.org/10.1038/sj.onc.1210008 . https://www.nature.com/articles/1210008#supplementary-information

doi: 10.1038/sj.onc.1210008 pubmed: 17043658

Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH (2012) The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 1826(2):272–296. https://doi.org/10.1016/j.bbcan.2012.04.008

doi: 10.1016/j.bbcan.2012.04.008 pubmed: 22579961 pmcid: 3788359

Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, Willbanks A, Sarkar S (2015) EMT and tumor metastasis. Clin Transl Med 4(1):6. https://doi.org/10.1186/s40169-015-0048-3

doi: 10.1186/s40169-015-0048-3 pubmed: 25852822 pmcid: 4385028

Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12):1776–1784. https://doi.org/10.1172/JCI20530

doi: 10.1172/JCI20530 pubmed: 14679171 pmcid: 297008

Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428. https://doi.org/10.1172/JCI39104

doi: 10.1172/JCI39104 pubmed: 19487818 pmcid: 2689101

Valastyan S, Weinberg Robert A (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275–292. https://doi.org/10.1016/j.cell.2011.09.024

doi: 10.1016/j.cell.2011.09.024 pubmed: 22000009 pmcid: 3261217

Liu Y, Cao X (2016) Characteristics and significance of the pre-metastatic niche. Cancer Cell 30(5):668–681. https://doi.org/10.1016/j.ccell.2016.09.011

doi: 10.1016/j.ccell.2016.09.011 pubmed: 27846389

Cao H, Xu E, Liu H, Wan L, Lai M (2015) Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review. Pathol Res Pract 211(8):557–569. https://doi.org/10.1016/j.prp.2015.05.010

doi: 10.1016/j.prp.2015.05.010 pubmed: 26092594

Bielenberg DR, Zetter BR (2015) The contribution of angiogenesis to the process of metastasis. Cancer J 21(4):267–273. https://doi.org/10.1097/ppo.0000000000000138

doi: 10.1097/ppo.0000000000000138 pubmed: 26222078 pmcid: 4670555

Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4:118. https://doi.org/10.1038/nrc1276

doi: 10.1038/nrc1276 pubmed: 14964308

Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66(5):2725–2731. https://doi.org/10.1158/0008-5472.can-05-3719

doi: 10.1158/0008-5472.can-05-3719 pubmed: 16510593

Eckert Mark A, Lwin Thinzar M, Chang Andrew T, Kim J, Danis E, Ohno-Machado L, Yang J (2011) Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19(3):372–386. https://doi.org/10.1016/j.ccr.2011.01.036

doi: 10.1016/j.ccr.2011.01.036 pubmed: 21397860 pmcid: 3072410

Zhu Q-Q, Ma C, Wang Q, Song Y, Lv T (2016) The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumor Biol 37(1):185–197. https://doi.org/10.1007/s13277-015-4450-7

doi: 10.1007/s13277-015-4450-7

Linder S (2007) The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 17(3):107–117. https://doi.org/10.1016/j.tcb.2007.01.002

doi: 10.1016/j.tcb.2007.01.002 pubmed: 17275303

Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC (2010) Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 51(2):545–556. https://doi.org/10.1002/hep.23311

doi: 10.1002/hep.23311 pubmed: 19957372

Chaturvedi P, Gilkes DM, Takano N, Semenza GL (2014) Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci 111(20):E2120–E2129. https://doi.org/10.1073/pnas.1406655111

doi: 10.1073/pnas.1406655111 pubmed: 24799675 pmcid: 4034192

Poggi A, Musso A, Dapino I, Zocchi MR (2014) Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 159(1):55–72. https://doi.org/10.1016/j.imlet.2014.03.001

doi: 10.1016/j.imlet.2014.03.001 pubmed: 24657523

Noy R, Pollard Jeffrey W (2014) Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity 41(1):49–61. https://doi.org/10.1016/j.immuni.2014.06.010

doi: 10.1016/j.immuni.2014.06.010 pubmed: 25035953 pmcid: 4137410

Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, Zhao L, Chen FH, Wang XT, You QD, Guo QL (2011) HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 19:284. https://doi.org/10.1038/cdd.2011.95 . https://www.nature.com/articles/cdd201195#supplementary-information

doi: 10.1038/cdd.2011.95 pubmed: 21818118 pmcid: 3263503

Shao S, Zhao X, Zhang X, Luo M, Zuo X, Huang S, Wang Y, Gu S, Zhao X (2015) Notch1 signaling regulates the epithelial–mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer 14(1):28. https://doi.org/10.1186/s12943-015-0295-3

doi: 10.1186/s12943-015-0295-3 pubmed: 25645291 pmcid: 4322803

Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS, Dinh DE (2011) Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol 38(3):733–744. https://doi.org/10.3892/ijo.2010.883

doi: 10.3892/ijo.2010.883 pubmed: 21181094

Tian B, Chen X, Zhang H, Li X, Wang J, Han W, Zhang LY, Fu L, Li Y, Nie C, Zhao Y, Tan X, Wang H, Guan XY, Hong A (2017) Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. Oncotarget 8(26):42300–42313. https://doi.org/10.18632/oncotarget.15857

doi: 10.18632/oncotarget.15857 pubmed: 28404945 pmcid: 5522068

Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT CJTA, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222. https://doi.org/10.1038/nature04695 . https://www.nature.com/articles/nature04695#supplementary-information

doi: 10.1038/nature04695 pubmed: 16642001

Smith-Mungo LI, Kagan HM (1998) Lysyl oxidase: Properties, regulation and multiple functions in biology. Matrix Biol 16(7):387–398. https://doi.org/10.1016/S0945-053X(98)90012-9

doi: 10.1016/S0945-053X(98)90012-9 pubmed: 9524359

Baker A-M, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, Reynolds AR, Cox TR, Erler JT (2013) Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res 73(2):583–594. https://doi.org/10.1158/0008-5472.can-12-2447

doi: 10.1158/0008-5472.can-12-2447 pubmed: 23188504

Semenza GL (2009) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625. https://doi.org/10.1038/onc.2009.441

doi: 10.1038/onc.2009.441 pubmed: 19946328 pmcid: 2969168

Weijer R, Broekgaarden M, Kos M, van Vught R, Rauws EAJ, Breukink E, van Gulik TM, Storm G, Heger M (2015) Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. J Photochem Photobiol C Photchem Rev 23:103–131. https://doi.org/10.1016/j.jphotochemrev.2015.05.002

doi: 10.1016/j.jphotochemrev.2015.05.002

Weijer R, Clavier S, Zaal EA, Pijls MM, van Kooten RT, Vermaas K, Leen R, Jongejan A, Moerland PD, van Kampen AH, van Kuilenburg AB, Berkers CR, Lemeer S, Heger M (2017) Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. Cell Mol Life Sci 74(6):1133–1151. https://doi.org/10.1007/s00018-016-2401-0

doi: 10.1007/s00018-016-2401-0 pubmed: 27803950

Reiss M, Brash DE, Muñoz-Antonia T, Simon JA, Ziegler A, Vellucci VF, Zhou ZL (1992) Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 4(8–9):349–357

pubmed: 1486218

Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3):304–317. https://doi.org/10.1016/j.ccr.2014.01.021

doi: 10.1016/j.ccr.2014.01.021 pubmed: 24651012 pmcid: 3970583

Lamberti MJ, Pansa MF, Vera RE, Fernández-Zapico ME, Rumie Vittar NB, Rivarola VA (2017) Transcriptional activation of HIF-1 by a ROS-ERK axis underlies the resistance to photodynamic therapy. PLoS One 12(5):e0177801. https://doi.org/10.1371/journal.pone.0177801

doi: 10.1371/journal.pone.0177801 pubmed: 28545088 pmcid: 5435305

Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60(15):4066–4069

pubmed: 10945611

Zhan Q, Yue W, Hu S (2011) Effect of photodynamic therapy and endostatin on human glioma xenografts in nude mice. Photodiagnosis Photodyn Ther 8(4):314–320. https://doi.org/10.1016/j.pdpdt.2011.04.002

doi: 10.1016/j.pdpdt.2011.04.002 pubmed: 22122918

Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL (2001) Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61(5):1830–1832

pubmed: 11280732

Roell KR, Reif DM, Motsinger-Reif AA (2017) An introduction to terminology and methodology of chemical synergy—perspectives from across disciplines. Front Pharmacol 8:158. https://doi.org/10.3389/fphar.2017.00158

doi: 10.3389/fphar.2017.00158 pubmed: 28473769 pmcid: 5397413

Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277(33):29936–29944. https://doi.org/10.1074/jbc.M204733200

doi: 10.1074/jbc.M204733200 pubmed: 12052835

Solár P, Chytilová M, Solárová Z, Mojžiš J, Ferenc P, Fedoročko P (2011) Photodynamic Therapy with hypericin improved by targeting HSP90 associated proteins. Pharmaceuticals 4(11):1488

doi: 10.3390/ph4111488 pubmed: 27721334 pmcid: 4060136

Al-Saigh R, Siopi M, Siafakas N, Velegraki A, Zerva L, Meletiadis J (2013) Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57(8):3713–3718. https://doi.org/10.1128/aac.02484-12

doi: 10.1128/aac.02484-12 pubmed: 23716054 pmcid: 3719712

Tsujino I, Miyagi K, Sampson RW, Sieber F (2006) Potentiation of the antitumor effect of merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B. Photochem Photobiol 82(2):458–465. https://doi.org/10.1562/2005-09-02-ra-672

doi: 10.1562/2005-09-02-ra-672 pubmed: 16613499 pmcid: 1626648

Campbell EJ, Vissers MCM, Bozonet S, Dyer A, Robinson BA, Dachs GU (2015) Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo−/− mice. Cancer Med 4(2):303–314. https://doi.org/10.1002/cam4.349

doi: 10.1002/cam4.349 pubmed: 25354695

Kramarenko GG, Wilke WW, Dayal D, Buettner GR, Schafer FQ (2006) Ascorbate enhances the toxicity of the photodynamic action of Verteporfin in HL-60 cells. Free Radic Biol Med 40(9):1615–1627. https://doi.org/10.1016/j.freeradbiomed.2005.12.027

doi: 10.1016/j.freeradbiomed.2005.12.027 pubmed: 16632121 pmcid: 2626188

Donald G, Hertzer K, Eibl G (2012) Baicalein--an intriguing therapeutic phytochemical in pancreatic cancer. Curr Drug Targets 13(14):1772–1776. https://doi.org/10.2174/138945012804545470

doi: 10.2174/138945012804545470 pubmed: 23140288 pmcid: 3678518

Tong WG, Ding XZ, Witt RC, Adrian TE (2002) Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1(11):929–935

pubmed: 12481414

Ding X-Z, Tong W-G, Adrian TE (2001) 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int J Cancer 94(5):630–636. https://doi.org/10.1002/ijc.1527

doi: 10.1002/ijc.1527 pubmed: 11745456

Ding X-Z, Kuszynski CA, El-Metwally TH, Adrian TE (1999) Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 266(2):392–399. https://doi.org/10.1006/bbrc.1999.1824

doi: 10.1006/bbrc.1999.1824 pubmed: 10600514

Ding X-Z, Iversen P, Cluck MW, Knezetic JA, Adrian TE (1999) Lipoxygenase Inhibitors Abolish Proliferation of Human Pancreatic Cancer Cells. Biochem Biophys Res Commun 261(1):218–223. https://doi.org/10.1006/bbrc.1999.1012

doi: 10.1006/bbrc.1999.1012 pubmed: 10405349

Triantafyllou A, Mylonis I, Simos G, Bonanou S, Tsakalof A (2008) Flavonoids induce HIF-1α but impair its nuclear accumulation and activity. Free Radic Biol Med 44(4):657–670. https://doi.org/10.1016/j.freeradbiomed.2007.10.050

doi: 10.1016/j.freeradbiomed.2007.10.050 pubmed: 18061585

Kleban J, Mikes J, Szilardiova B, Koval J, Sackova V, Solar P, Horvath V, Hofmanova J, Kozubik A, Fedorocko P (2007) Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. Photochem Photobiol 83(5):1174–1185. https://doi.org/10.1111/j.1751-1097.2007.00127.x

doi: 10.1111/j.1751-1097.2007.00127.x pubmed: 17880512

Hamsa TP, Kuttan G (2012) Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem Toxicol 35(1):57–70. https://doi.org/10.3109/01480545.2011.589437

doi: 10.3109/01480545.2011.589437 pubmed: 22145808

Luiza Andreazza N, Vevert-Bizet C, Bourg-Heckly G, Sureau F, Jose Salvador M, Bonneau S (2016) Berberine as a photosensitizing agent for antitumoral photodynamic therapy: insights into its association to low density lipoproteins. Int J Pharm 510(1):240–249. https://doi.org/10.1016/j.ijpharm.2016.06.009

doi: 10.1016/j.ijpharm.2016.06.009 pubmed: 27282536

Pan Y, Shao D, Zhao Y, Zhang F, Zheng X, Tan Y, He K, Li J, Chen L (2017) Berberine Reverses hypoxia-induced chemoresistance in breast cancer through the inhibition of AMPK- HIF-1α. Int J Biol Sci 13(6):794–803. https://doi.org/10.7150/ijbs.18969

doi: 10.7150/ijbs.18969 pubmed: 28656004 pmcid: 5485634

Bonvini P, Zorzi E, Basso G, Rosolen A (2007) Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 21(4):838–842. https://doi.org/10.1038/sj.leu.2404528

doi: 10.1038/sj.leu.2404528 pubmed: 17268529

Shin DH, Chun YS, Lee DS, Huang LE, Park JW (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111(6):3131–3136. https://doi.org/10.1182/blood-2007-11-120576

doi: 10.1182/blood-2007-11-120576 pubmed: 18174379

Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P (2012) Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med 90(1):45–54. https://doi.org/10.1007/s00109-011-0805-8

doi: 10.1007/s00109-011-0805-8 pubmed: 21909688

Li Z, Agharkar P, Chen B (2013) Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function. Cancer Lett 339(1):128–134. https://doi.org/10.1016/j.canlet.2013.07.012

doi: 10.1016/j.canlet.2013.07.012 pubmed: 23872275

Gillies HC, Herriott D, Liang R, Ohashi K, Rogers HJ, Harper PG (1987) Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 23(3):303–310

doi: 10.1111/j.1365-2125.1987.tb03049.x pubmed: 3471265 pmcid: 1386228

Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci 106(7):2353–2358. https://doi.org/10.1073/pnas.0812801106

doi: 10.1073/pnas.0812801106 pubmed: 19168635 pmcid: 2650160

Tokarska K, Lamch Ł, Piechota B, Żukowski K, Chudy M, Wilk KA, Brzózka Z (2020) Co-delivery of IR-768 and daunorubicin using mPEG-b-PLGA micelles for synergistic enhancement of combination therapy of melanoma. J Photochem Photobiol B Biol 211:111981. https://doi.org/10.1016/j.jphotobiol.2020.111981

doi: 10.1016/j.jphotobiol.2020.111981

Zhang H, Chen B, Jiang H, Wang C, Wang H, Wang X (2011) A strategy for ZnO nanorod mediated multi-mode cancer treatment. Biomaterials 32(7):1906–1914. https://doi.org/10.1016/j.biomaterials.2010.11.027

doi: 10.1016/j.biomaterials.2010.11.027 pubmed: 21145104

Hariharan R, Senthilkumar S, Suganthi A, Rajarajan M (2013) Synthesis and characterization of daunorubicin modified ZnO/PVP nanorods and its photodynamic action. J Photochem Photobiol A Chem 252:107–115. https://doi.org/10.1016/j.jphotochem.2012.11.017

doi: 10.1016/j.jphotochem.2012.11.017

Graham KA, Kulawiec M, Owens KM, Li X, Desouki MM, Chandra D, Singh KK (2010) NADPH oxidase 4 is an oncoprotein localized to mitochondria. Cancer Biol Ther 10(3):223–231. https://doi.org/10.4161/cbt.10.3.12207

doi: 10.4161/cbt.10.3.12207 pubmed: 20523116 pmcid: 3040835

Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, Juhasz A (2013) Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts. Free Radic Biol Med 57:162–175. https://doi.org/10.1016/j.freeradbiomed.2013.01.002

doi: 10.1016/j.freeradbiomed.2013.01.002 pubmed: 23314043 pmcid: 3594408

Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH (2007) Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67(22):10823–10830. https://doi.org/10.1158/0008-5472.can-07-0783

doi: 10.1158/0008-5472.can-07-0783 pubmed: 18006827

Chernyak BV, Izyumov DS, Lyamzaev KG, Pashkovskaya AA, Pletjushkina OY, Antonenko YN, Sakharov DV, Wirtz KW, Skulachev VP (2006) Production of reactive oxygen species in mitochondria of HeLa cells under oxidative stress. Biochim Biophys Acta 1757(5–6):525–534. https://doi.org/10.1016/j.bbabio.2006.02.019

doi: 10.1016/j.bbabio.2006.02.019 pubmed: 16678116

Rubio N, Rajadurai A, Held KD, Prise KM, Liber HL, Redmond RW (2009) Real-time imaging of novel spatial and temporal responses to photodynamic stress. Free Radic Biol Med 47(3):283–290. https://doi.org/10.1016/j.freeradbiomed.2009.04.024

doi: 10.1016/j.freeradbiomed.2009.04.024 pubmed: 19409981

Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A, Sapino A (2012) HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12:4. https://doi.org/10.1186/1471-2407-12-4

doi: 10.1186/1471-2407-12-4 pubmed: 22217342 pmcid: 3262753

Chang J-E, Yoon I-S, Sun P-L, Yi E, Jheon S, Shim C-K (2014) Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer. J Photochem Photobiol B Biol 140:49–56. https://doi.org/10.1016/j.jphotobiol.2014.07.005

doi: 10.1016/j.jphotobiol.2014.07.005

Lippert BM, Teymoortash A, Külkens C, Folz BJ, Werner JA (2004) Photodynamic effects of anthracyclin derivatives on squamous cell carcinoma cell lines of the head and neck. Lasers Surg Med 34(5):391–397. https://doi.org/10.1002/lsm.20040

doi: 10.1002/lsm.20040 pubmed: 15216532

Jendželovská Z, Jendželovský R, Kuchárová B, Fedoročko P (2016) Hypericin in the light and in the dark: two sides of the same coin. Front Plant Sci 7:560. https://doi.org/10.3389/fpls.2016.00560

doi: 10.3389/fpls.2016.00560 pubmed: 27200034 pmcid: 4859072

Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G (2011) Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PLoS One 6(9):e22849. https://doi.org/10.1371/journal.pone.0022849

doi: 10.1371/journal.pone.0022849 pubmed: 21949677 pmcid: 3176203

Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12(7):363–369

pubmed: 11457733

Zhang X, Cai L, He J, Li X, Li L, Chen X, Lan P (2017) Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma. Photodiagnosis Photodyn Ther 20:78–85. https://doi.org/10.1016/j.pdpdt.2017.08.004

doi: 10.1016/j.pdpdt.2017.08.004 pubmed: 28811223

Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65(19):9021–9028. https://doi.org/10.1158/0008-5472.can-04-4095

doi: 10.1158/0008-5472.can-04-4095 pubmed: 16204076 pmcid: 6623969

Soares HT, Campos JRS, Gomes-da-Silva LC, Schaberle FA, Dabrowski JM, Arnaut LG (2016) Pro-oxidant and antioxidant effects in photodynamic therapy: cells recognise that not all exogenous ROS are alike. Chem Bio Chem 17(9):836–842. https://doi.org/10.1002/cbic.201500573

doi: 10.1002/cbic.201500573 pubmed: 26891856

Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilczynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, Jalili A, Kopec M, Grzela T, Jakobisiak M (2003) Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem 278(1):407–414. https://doi.org/10.1074/jbc.M209125200

doi: 10.1074/jbc.M209125200 pubmed: 12409296

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7(6):1472–1482. https://doi.org/10.1158/1535-7163.mct-08-0107

doi: 10.1158/1535-7163.mct-08-0107 pubmed: 18566218

Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114. https://doi.org/10.2165/00003088-199936020-00002

doi: 10.2165/00003088-199936020-00002 pubmed: 10092957

Li W, Peng J, Tan L, Wu J, Shi K, Qu Y, Wei X, Qian Z (2016) Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles. Biomaterials 106:119–133. https://doi.org/10.1016/j.biomaterials.2016.08.016

doi: 10.1016/j.biomaterials.2016.08.016 pubmed: 27561883

Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH (2002) G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 110(1):91–99. https://doi.org/10.1172/jci13275

doi: 10.1172/jci13275 pubmed: 12093892 pmcid: 151025

Diez B, Ernst G, Teijo MJ, Batlle A, Hajos S, Fukuda H (2012) Combined chemotherapy and ALA-based photodynamic therapy in leukemic murine cells. Leuk Res 36(9):1179–1184. https://doi.org/10.1016/j.leukres.2012.04.027

doi: 10.1016/j.leukres.2012.04.027 pubmed: 22613191

Jung HJ, Seo I, Jha BK, Suh SI, Suh MH, Baek WK (2014) Minocycline inhibits angiogenesis in vitro through the translational suppression of HIF-1alpha. Arch Biochem Biophys 545:74–82. https://doi.org/10.1016/j.abb.2013.12.023

doi: 10.1016/j.abb.2013.12.023 pubmed: 24412777

Lee M-J, Hung S-H, Huang M-C, Tsai T, Chen C-T (2017) Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. PLoS One 12(5):e0178493. https://doi.org/10.1371/journal.pone.0178493

doi: 10.1371/journal.pone.0178493 pubmed: 28558025 pmcid: 5448821

Li J, Kim SG, Blenis J (2014) Rapamycin: one drug, many effects. Cell Metab 19(3):373–379. https://doi.org/10.1016/j.cmet.2014.01.001

doi: 10.1016/j.cmet.2014.01.001 pubmed: 24508508 pmcid: 3972801

Masoud GN, Li W (2015) HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmac Sin B 5(5):378–389. https://doi.org/10.1016/j.apsb.2015.05.007

doi: 10.1016/j.apsb.2015.05.007

Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420–1424. https://doi.org/10.1038/sj.bjc.6602162

doi: 10.1038/sj.bjc.6602162 pubmed: 15365568 pmcid: 2409926

Wang YD, Su YJ, Li JY, Yao XC, Liang GJ (2015) Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1. Int J Clin Exp Pathol 8(5):5182–5188

pubmed: 26191215 pmcid: 4503087

Weyergang A, Berg K, Kaalhus O, Peng Q, Selbo PK (2009) Photodynamic therapy targets the mTOR signaling network in vitro and in vivo. Mol Pharm 6(1):255–264. https://doi.org/10.1021/mp800156e

doi: 10.1021/mp800156e pubmed: 19125612

Tuo J, Wang Q, Zouboulis CC, Liu Y, Ma Y, Ma L, Ying J, Zhang C, Xiang L (2017) ALA-PDT suppressing the cell growth and reducing the lipogenesis in human SZ95 sebocytes by mTOR signaling pathway in vitro. Photodiagnosis Photodyn Ther 18:295–301. https://doi.org/10.1016/j.pdpdt.2017.03.006

doi: 10.1016/j.pdpdt.2017.03.006 pubmed: 28330814

Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4(10):1465–1474. https://doi.org/10.1158/1535-7163.mct-05-0198

doi: 10.1158/1535-7163.mct-05-0198 pubmed: 16227395

Singh RP, Gu M, Agarwal R (2008) Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68(6):2043–2050. https://doi.org/10.1158/0008-5472.can-07-6247

doi: 10.1158/0008-5472.can-07-6247 pubmed: 18339887

Zhang X, Liu X, Kang S, Liu C, Hao Y (2018) Resveratrol enhances the effects of ALA-PDT on skin squamous cells A431 through p38/ MAPK signaling pathway. Cancer Biomark 21(4):797–803. https://doi.org/10.3233/cbm-170495

doi: 10.3233/cbm-170495 pubmed: 29286920

Gandara L, Sandes E, Di Venosa G, Prack Mc Cormick B, Rodriguez L, Mamone L, Batlle A, Eijan AM, Casas A (2014) The natural flavonoid silybin improves the response to photodynamic therapy of bladder cancer cells. J Photochem Photobiol B Biol 133:55–64. https://doi.org/10.1016/j.jphotobiol.2014.03.006

doi: 10.1016/j.jphotobiol.2014.03.006

García-Maceira P, Mateo J (2008) Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28:313. https://doi.org/10.1038/onc.2008.398 . https://www.nature.com/articles/onc2008398#supplementary-information

doi: 10.1038/onc.2008.398 pubmed: 18978810

Kamiyama H, Takano S, Tsuboi K, Matsumura A (2005) Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131(4):205–213. https://doi.org/10.1007/s00432-004-0642-z

doi: 10.1007/s00432-004-0642-z pubmed: 15583935

Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1. Cancer Res 64(4):1475. https://doi.org/10.1158/0008-5472.CAN-03-3139

doi: 10.1158/0008-5472.CAN-03-3139 pubmed: 14983893

Peng CL, Lai PS, Lin FH, Yueh-Hsiu Wu S, Shieh MJ (2009) Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 30(21):3614–3625. https://doi.org/10.1016/j.biomaterials.2009.03.048

doi: 10.1016/j.biomaterials.2009.03.048 pubmed: 19395020

Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, Bae MK, Kim KW (2007) Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17(3):647–651

pubmed: 17273746

Bueno-Carrazco J, Castro-Leyva V, García-Gomez F, Solís-Paredes M, Ramon-Gallegos E, Cruz-Orea A, Eguía-Aguilar P, Arenas-Huertero F (2012) Sodium butyrate increases the effect of the photodynamic therapy: a mechanism that involves modulation of gene expression and differentiation in astrocytoma cells. Childs Nerv Syst 28(10):1723–1730. https://doi.org/10.1007/s00381-012-1828-3

doi: 10.1007/s00381-012-1828-3 pubmed: 22710635

Flores-Ancona RM, Garcia-Gomez FY, Jimenez-Betanzos AM, Solis-Paredes M, Castro-Leyva V, Cruz-Orea A, Arenas-Huertero F, Ramon-Gallegos E (2009) Effects of sodium butyrate on cell death induced by photodynamic therapy in U373-MG and D54-MG astrocytoma cell lines. Photochem Photobiol 85(5):1182–1188. https://doi.org/10.1111/j.1751-1097.2009.00561.x

doi: 10.1111/j.1751-1097.2009.00561.x pubmed: 19453389

L-p L, Ho RLK, Chen GG, Lai PBS (2012) Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18(20):5662–5671. https://doi.org/10.1158/1078-0432.ccr-12-0552

doi: 10.1158/1078-0432.ccr-12-0552

Weiss A, van Beijnum JR, Bonvin D, Jichlinski P, Dyson PJ, Griffioen AW, Nowak-Sliwinska P (2014) Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med 18(3):480–491. https://doi.org/10.1111/jcmm.12199

doi: 10.1111/jcmm.12199 pubmed: 24450440 pmcid: 3955154

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH, Melillo G (2011) Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 17(15):5123–5131. https://doi.org/10.1158/1078-0432.ccr-11-0682

doi: 10.1158/1078-0432.ccr-11-0682 pubmed: 21673063 pmcid: 3149769

Goler-Baron V, Assaraf YG (2012) Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS One 7(4):e35487. https://doi.org/10.1371/journal.pone.0035487

doi: 10.1371/journal.pone.0035487 pubmed: 22530032 pmcid: 3329466

Knuth J, Sharma SJ, Würdemann N, Holler C, Garvalov BK, Acker T, Wittekindt C, Wagner S, Klussmann JP (2017) Hypoxia-inducible factor-1α activation in HPV-positive head and neck squamous cell carcinoma cell lines. Oncotarget 8(52):89681–89691. https://doi.org/10.18632/oncotarget.20813

doi: 10.18632/oncotarget.20813 pubmed: 29163780 pmcid: 5685701

Halaburkova A, Jendzelovsky R, Koval J, Herceg Z, Fedorocko P, Ghantous A (2017) Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A. Clin Epigenetics 9:62. https://doi.org/10.1186/s13148-017-0359-x

doi: 10.1186/s13148-017-0359-x pubmed: 28603560 pmcid: 5465463

Kang FW, Que L, Wu M, Wang ZL, Sun J (2012) Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol Rep 28(1):193–199. https://doi.org/10.3892/or.2012.1784

doi: 10.3892/or.2012.1784 pubmed: 22552321

Lee HJ, Kim KW (2012) Suppression of HIF-1α by valproic acid sustains self-renewal of mouse embryonic stem cells under hypoxia in vitro. Biomol Therap 20(3):280–285. https://doi.org/10.4062/biomolther.2012.20.3.280

doi: 10.4062/biomolther.2012.20.3.280

Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J, Sun X, Li J (2017) Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci 108(3):478–487. https://doi.org/10.1111/cas.13138

doi: 10.1111/cas.13138 pubmed: 28002618 pmcid: 5378285

Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, Gragoudas E, Vavvas DG (2014) The clinically used photosensitizer verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res 124:67–73. https://doi.org/10.1016/j.exer.2014.04.011

doi: 10.1016/j.exer.2014.04.011 pubmed: 24837142 pmcid: 4135181

Bousquet MS, Ma JJ, Ratnayake R, Havre PA, Yao J, Dang NH, Paul VJ, Carney TJ, Dang LH, Luesch H (2016) Multidimensional screening platform for simultaneously targeting oncogenic kras and hypoxia-inducible factors pathways in colorectal cancer. ACS Chem Biol 11(5):1322–1331. https://doi.org/10.1021/acschembio.5b00860

doi: 10.1021/acschembio.5b00860 pubmed: 26938486 pmcid: 4874856

Celli JP, Solban N, Liang A, Pereira SP, Hasan T (2011) Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med 43(7):565–574. https://doi.org/10.1002/lsm.21093

doi: 10.1002/lsm.21093 pubmed: 22057484 pmcid: 3211106

Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M (2014) The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One 9(8):e106224. https://doi.org/10.1371/journal.pone.0106224

doi: 10.1371/journal.pone.0106224 pubmed: 25166596 pmcid: 4148404

Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y (2016) Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J Cancer Res Clin Oncol 142(2):379–387. https://doi.org/10.1007/s00432-015-2026-y

doi: 10.1007/s00432-015-2026-y pubmed: 26314218

Kessel D, Vicente MG, Reiners JJ Jr (2006) Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg Med 38(5):482–488. https://doi.org/10.1002/lsm.20334

doi: 10.1002/lsm.20334 pubmed: 16615135 pmcid: 2749509

Ibrahim NO, Hahn T, Franke C, Stiehl DP, Wirthner R, Wenger RH, Katschinski DM (2005) Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res 65(23):11094–11100. https://doi.org/10.1158/0008-5472.can-05-1877

doi: 10.1158/0008-5472.can-05-1877 pubmed: 16322259

Lang W, Caldwell GW, Li J, Leo GC, Jones WJ, Masucci JA (2007) Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos 35(1):21–29. https://doi.org/10.1124/dmd.106.009639

doi: 10.1124/dmd.106.009639 pubmed: 17012542

Newman B, Liu Y, Lee HF, Sun D, Wang Y (2012) HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res 72(17):4551–4561. https://doi.org/10.1158/0008-5472.can-11-3600

doi: 10.1158/0008-5472.can-11-3600 pubmed: 22751135 pmcid: 3443561

Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, Horiba MN, Egorin MJ, Ivy P, Pacey S, Lorusso PM (2010) Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 16(14):3795–3804. https://doi.org/10.1158/1078-0432.ccr-10-0503

doi: 10.1158/1078-0432.ccr-10-0503 pubmed: 20525756 pmcid: 2909581

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R (2004) Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10(14):4813–4821. https://doi.org/10.1158/1078-0432.ccr-03-0795

doi: 10.1158/1078-0432.ccr-03-0795 pubmed: 15269157

Joshi SS, Jiang S, Unni E, Goding SR, Fan T, Antony PA, Hornyak TJ (2018) 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model. PLoS One 13(2):e0191264. https://doi.org/10.1371/journal.pone.0191264

doi: 10.1371/journal.pone.0191264 pubmed: 29481571 pmcid: 5826531

Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56(2):126–137. https://doi.org/10.1007/s00280-004-0947-2

doi: 10.1007/s00280-004-0947-2 pubmed: 15841378

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17(6):1561–1570. https://doi.org/10.1158/1078-0432.ccr-10-1927

doi: 10.1158/1078-0432.ccr-10-1927 pubmed: 21278242 pmcid: 3060938

Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363–375. https://doi.org/10.1016/S1535-6108(03)00077-1

doi: 10.1016/S1535-6108(03)00077-1 pubmed: 12726862

Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg IIW (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1):22–27. https://doi.org/10.4161/cbt.5.1.2349

doi: 10.4161/cbt.5.1.2349 pubmed: 16357512

Kambhampati S, Rajewski RA, Tanol M, Haque I, Das A, Banerjee S, Jha S, Burns D, Borrego-Diaz E, Van Veldhuizen P, Banerjee SK (2013) A second generation 2-methoxyestradiol prodrug is effective against Barrett’s adenocarcinoma in a mouse xenograft model. Mol Cancer Ther 12(3):255–263. https://doi.org/10.1158/1535-7163.mct-12-0777

doi: 10.1158/1535-7163.mct-12-0777 pubmed: 23288782 pmcid: 4729448

Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK, Kim HM, Kwon BM, Lee JJ, Lee K (2009) A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 385(1):16–21. https://doi.org/10.1016/j.bbrc.2009.05.022

doi: 10.1016/j.bbrc.2009.05.022 pubmed: 19433063

Rietbrock N, Abshagen U, Bergmann KV, Kewitz H (1972) Pharmacokinetics of digoxin and its 4‴-acetyl-and methylderivates in the rat. Naunyn Schmiedebergs Arch Pharmacol 274(2):171–181. https://doi.org/10.1007/bf00501851

doi: 10.1007/bf00501851 pubmed: 4262277

Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL (2008) Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci U S A 105(50):19579–19586. https://doi.org/10.1073/pnas.0809763105

doi: 10.1073/pnas.0809763105 pubmed: 19020076 pmcid: 2604945

Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106(42):17910–17915. https://doi.org/10.1073/pnas.0909353106

doi: 10.1073/pnas.0909353106 pubmed: 19805192 pmcid: 2764905

Dana S, Prusty D, Dhayal D, Gupta MK, Dar A, Sen S, Mukhopadhyay P, Adak T, Dhar SK (2014) Potent antimalarial activity of acriflavine in vitro and in vivo. ACS Chem Biol 9(10):2366–2373. https://doi.org/10.1021/cb500476q

doi: 10.1021/cb500476q pubmed: 25089658 pmcid: 4201339

Jones DT, Pugh CW, Wigfield S, Stevens MF, Harris AL (2006) Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 12(18):5384–5394. https://doi.org/10.1158/1078-0432.ccr-05-2380

doi: 10.1158/1078-0432.ccr-05-2380 pubmed: 17000671

Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G (2010) Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor, Inhibits HIF-1α Expression in an AhR-Independent Fashion. Cancer Res 70(17):6837–6848. https://doi.org/10.1158/0008-5472.can-10-1075

doi: 10.1158/0008-5472.can-10-1075 pubmed: 20736373 pmcid: 2932848

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA (2004) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3(6):715–725

pubmed: 15210858

Osada M, Imaoka S, Funae Y (2004) Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1α protein. FEBS Letters 575(1–3):59–63. https://doi.org/10.1016/j.febslet.2004.08.036

doi: 10.1016/j.febslet.2004.08.036 pubmed: 15388333

Gradolatto A, Basly J-P, Berges R, Teyssier C, Chagnon M-C, Siess M-H, Canivenc-Lavier M-C (2005) Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab Dispos 33(1):49–54. https://doi.org/10.1124/dmd.104.000893

doi: 10.1124/dmd.104.000893 pubmed: 15466493

Park H-R, Daun Y, Keun Park J, Bark K-M (2013) Spectroscopic properties of flavonoids in various aqueous-organic solvent mixtures. Bull Korean Chem Soc 34. https://doi.org/10.5012/bkcs.2013.34.1.211

Ansó E, Zuazo A, Irigoyen M, Urdaci MC, Rouzaut A, Martínez-Irujo JJ (2010) Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol 79(11):1600–1609. https://doi.org/10.1016/j.bcp.2010.02.004

doi: 10.1016/j.bcp.2010.02.004 pubmed: 20153296

Jeong YJ, Cho HJ, Magae J, Lee IK, Park KG, Chang YC (2013) Ascofuranone suppresses EGF-induced HIF-1alpha protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 273(3):542–550. https://doi.org/10.1016/j.taap.2013.09.027

doi: 10.1016/j.taap.2013.09.027 pubmed: 24096035

Sawada M, Hosokawa T, Okutomi T, Ando K (1973) Hypolipidemic property of ascofuranone. J Antibiot 26(11):681–686

doi: 10.7164/antibiotics.26.681

Sasaki H, Hosokawa T, Sawada M, Ando K (1973) Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity. J Antibiot 26(11):676–680. https://doi.org/10.7164/antibiotics.26.676

doi: 10.7164/antibiotics.26.676

Xu D, Chen Q, Liu Y, Wen X (2017) Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction. Oncotarget 8:105561–105573. https://doi.org/10.18632/oncotarget.22319

doi: 10.18632/oncotarget.22319 pubmed: 29285272 pmcid: 5739659

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, Ehrmann A, Summer H, Flamme I, Oehme F, Thierauch K, Michels M, Hess-Stumpp H, Ziegelbauer K (2013) BAY 87–2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med 2(5):611–624. https://doi.org/10.1002/cam4.112

doi: 10.1002/cam4.112 pubmed: 24403227 pmcid: 3892793

Lin S, Tsai SC, Lee CC, Wang BW, Liou JY, Shyu KG (2004) Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol 66(3):612–619

pubmed: 15322253

Gong Z, Chen Y, Zhang R, Yang Q, Wang Y, Guo Y, Zhou B, Weng X, Liu X, Li Y, Zhu X, Dong Y (2015) Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism. Arch Pharm Res 38(10):1888–1896. https://doi.org/10.1007/s12272-015-0568-9

doi: 10.1007/s12272-015-0568-9 pubmed: 25716428

Vicas L, Teusdea A, Vicas S, Marian E, Tunde J, Muresan M, Gligor F (2015) Assessment of antioxidant capacity of some extracts for further use in therapy. Farmacia 63:267–274

Walker SE, Charbonneau LF, Law S (2014) Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4 degrees C and room temperature (23 degrees C). Can J Hosp Pharm 67(2):102–107

pubmed: 24799719 pmcid: 4006754

Gunasekera SP, Imperial L, Garst C, Ratnayake R, Dang LH, Paul VJ, Luesch H (2016) Caldoramide, a modified pentapeptide from the marine cyanobacterium caldora penicillata. J Nat Prod 79(7):1867–1871. https://doi.org/10.1021/acs.jnatprod.6b00203

doi: 10.1021/acs.jnatprod.6b00203 pubmed: 27380142 pmcid: 5215049

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD (2014) Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer. Mol Cancer 13:91. https://doi.org/10.1186/1476-4598-13-91

doi: 10.1186/1476-4598-13-91 pubmed: 24775564 pmcid: 4113146

Frye SV, Heightman T, Jin J (2010) Chapter 20 - Targeting methyl lysine. In: Macor JE (ed) Annual reports in medicinal chemistry, vol 45. Academic Press, London, pp 329–343. https://doi.org/10.1016/S0065-7743(10)45020-4

doi: 10.1016/S0065-7743(10)45020-4

Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli H-U, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1):33–43. https://doi.org/10.1016/j.ccr.2004.06.009

doi: 10.1016/j.ccr.2004.06.009 pubmed: 15261140

Na Y-R, Han K-C, Park H, Yang EG (2013) Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300. Biochem Biophys Res Commun 434(4):879–884. https://doi.org/10.1016/j.bbrc.2013.04.044

doi: 10.1016/j.bbrc.2013.04.044 pubmed: 23618863

Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J (2016) Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer 114(5):519–523. https://doi.org/10.1038/bjc.2016.20

doi: 10.1038/bjc.2016.20 pubmed: 26867162 pmcid: 4782210

Bae W-Y, Choi J-S, Kim J-E, Jeong J-W (2015) Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1α expression during tumor progression. Biochem Pharmacol 98(1):41–50. https://doi.org/10.1016/j.bcp.2015.08.095

doi: 10.1016/j.bcp.2015.08.095 pubmed: 26297910

Hong S-H, Ismail IA, Kang S-M, Han DC, Kwon B-M (2016) Cinnamaldehydes in cancer chemotherapy. Phytother Res 30(5):754–767. https://doi.org/10.1002/ptr.5592

doi: 10.1002/ptr.5592 pubmed: 26890810

Ng L-T, Wu S-J (2011) Antiproliferative activity of cinnamomum cassia constituents and effects of pifithrin-alpha on their apoptotic signaling pathways in Hep G2 cells. Evid Based Complement Alternat Med 2011:492148. https://doi.org/10.1093/ecam/nep220

doi: 10.1093/ecam/nep220 pubmed: 20038571 pmcid: 3135661

Ban HS, Xu X, Jang K, Kim I, Kim B-K, Lee K, Won M (2016) A novel malate dehydrogenase 2 inhibitor suppresses hypoxia-inducible factor-1 by regulating mitochondrial respiration. PLoS One 11(9):e0162568. https://doi.org/10.1371/journal.pone.0162568

doi: 10.1371/journal.pone.0162568 pubmed: 27611801 pmcid: 5017629

Naik R, Won M, Ban HS, Bhattarai D, Xu X, Eo Y, Hong YS, Singh S, Choi Y, Ahn HC, Lee K (2014) Synthesis and structure-activity relationship study of chemical probes as hypoxia induced factor-1alpha/malate dehydrogenase 2 inhibitors. J Med Chem 57(22):9522–9538. https://doi.org/10.1021/jm501241g

doi: 10.1021/jm501241g pubmed: 25356789

Jones DT, Harris AL (2006) Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 5(9):2193–2202. https://doi.org/10.1158/1535-7163.mct-05-0443

doi: 10.1158/1535-7163.mct-05-0443 pubmed: 16985052

Klausmeyer P, Zhou Q, Scudiero DA, Uranchimeg B, Melillo G, Cardellina JH, Shoemaker RH, Chang CJ, McCloud TG (2009) Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii. J Nat Prod 72(5):805–812. https://doi.org/10.1021/np8006342

doi: 10.1021/np8006342 pubmed: 19405508

Kaushik V, Azad N, Yakisich JS, Iyer AK (2017) Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers. Cell Death Dis 3:17009. https://doi.org/10.1038/cddiscovery.2017.9

doi: 10.1038/cddiscovery.2017.9

Ma J, Zi Jiang Y, Shi H, Mi C, Li J, Xing Nan J, Wu X, Joon Lee J, Jin X (2014) Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α. Eur J Pharmacol 723:46–54. https://doi.org/10.1016/j.ejphar.2013.12.005

doi: 10.1016/j.ejphar.2013.12.005 pubmed: 24333213

Molavi O, Shayeganpour A, Somayaji V, Hamdy S, Brocks DR, Lavasanifar A, Kwon GS, Samuel J (2006) Development of a sensitive and specific liquid chromatography/mass spectrometry method for the quantification of cucurbitacin I (JSI-124) in rat plasma. J Pharm Pharmac Sci 9(2):158–164

Nishida R, Yokoyama M, Fukami H (1992) Sequestration of cucurbitacin analogs by New and Old World chrysomelid leaf beetles in the tribe Luperini. Chemoecology 3(1):19–24. https://doi.org/10.1007/bf01261452

doi: 10.1007/bf01261452

Schulz V, Hänsel R, Blumenthal M, Tyler VE (2004) Rational phytotherapy : a reference guide for physicians and pharmacists

Dakeng S, Duangmano S, Jiratchariyakul W, U-Pratya Y, Bögler O, Patmasiriwat P (2012) Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: Reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus. J Cell Biochem 113(1):49–60. https://doi.org/10.1002/jcb.23326

doi: 10.1002/jcb.23326 pubmed: 21866566 pmcid: 3245346

Touihri-Barakati I, Kallech-Ziri O, Ayadi W, Kovacic H, Hanchi B, Hosni K, Luis J (2017) Cucurbitacin B purified from Ecballium elaterium (L.) A. Rich from Tunisia inhibits α5β1 integrin-mediated adhesion, migration, proliferation of human glioblastoma cell line and angiogenesis. Eur J Pharmacol 797:153–161. https://doi.org/10.1016/j.ejphar.2017.01.006

doi: 10.1016/j.ejphar.2017.01.006 pubmed: 28108377

Didiot M-C, Hewett J, Varin T, Freuler F, Selinger D, Nick H, Reinhardt J, Buckler A, Myer V, Schuffenhauer A, Guy CT, Parker CN (2013) Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation. J Biomol Screen 18(4):407–419. https://doi.org/10.1177/1087057112466698

doi: 10.1177/1087057112466698 pubmed: 23150017

Gervasoni JE Jr, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S (2004) An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res 24(5a):2617–2626

pubmed: 15517865

Bains OS, Szeitz A, Lubieniecka JM, Cragg GE, Grigliatti TA, Riggs KW, Reid RE (2013) A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmac Exp Therap 347(2):375. https://doi.org/10.1124/jpet.113.206805

doi: 10.1124/jpet.113.206805

Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G (2012) High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 3(10):1124–1136. https://doi.org/10.18632/oncotarget.707

doi: 10.18632/oncotarget.707 pubmed: 23165409 pmcid: 3717950

López-Lázaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortés F (2005) Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 68(11):1642–1645. https://doi.org/10.1021/np050226l

doi: 10.1021/np050226l pubmed: 16309315

Lin J, Carducci MA (2009) HIF-1α inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics. Expert Opin Investig Drugs 18(2):241–243. https://doi.org/10.1517/13543780802683081

doi: 10.1517/13543780802683081 pubmed: 19236270

Ouyang X, Han S-N, Zhang J-Y, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai S-Y, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ (2018) Digoxin suppresses pyruvate kinase M2-promoted HIF-1α; transactivation in steatohepatitis. Cell Metab 27(2):339–350.e333. https://doi.org/10.1016/j.cmet.2018.01.007

doi: 10.1016/j.cmet.2018.01.007 pubmed: 29414684 pmcid: 5806149

Wei D, Peng JJ, Gao H, Li H, Li D, Tan Y, Zhang T (2013) Digoxin downregulates NDRG1 and VEGF through the inhibition of HIF-1alpha under hypoxic conditions in human lung adenocarcinoma A549 cells. Int J Mol Sci 14(4):7273–7285. https://doi.org/10.3390/ijms14047273

doi: 10.3390/ijms14047273 pubmed: 23549264 pmcid: 3645685

Felth J, Rickardson L, Rosén J, Wickström M, Fryknäs M, Lindskog M, Bohlin L, Gullbo J (2009) Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs. J Nat Prod 72(11):1969–1974. https://doi.org/10.1021/np900210m

doi: 10.1021/np900210m pubmed: 19894733

Touza NA, Pôças ES, Quintas LE, Cunha-Filho G, Santos ML, Noël F (2011) Inhibitory effect of combinations of digoxin and endogenous cardiotonic steroids on Na+/K+-ATPase activity in human kidney membrane preparation. Life Sci 88(1–2):39–42. https://doi.org/10.1016/j.lfs.2010.10.027

doi: 10.1016/j.lfs.2010.10.027 pubmed: 21047518

Li J, Mi C, Ma J, Wang KS, Lee JJ, Jin X (2015) Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1α. Chem Biol Interact 240:48–58. https://doi.org/10.1016/j.cbi.2015.08.006

doi: 10.1016/j.cbi.2015.08.006 pubmed: 26282490

Cheng R, Chen J, Wang Y, Ge Y, Huang Z, Zhang G (2016) Dihydrotanshinone induces apoptosis of SGC7901 and MGC803 cells via activation of JNK and p38 signalling pathways. Pharm Biol 54(12):3019–3025. https://doi.org/10.1080/13880209.2016.1199045

doi: 10.1080/13880209.2016.1199045 pubmed: 27431278

Sun J, Yang M, Han J, Wang B, Ma X, Xu M, Liu P, Guo D (2007) Profiling the metabolic difference of seven tanshinones using high-performance liquid chromatography/multi-stage mass spectrometry with data-dependent acquisition. Rapid Commun Mass Spectrom 21(14):2211–2226. https://doi.org/10.1002/rcm.3080

doi: 10.1002/rcm.3080 pubmed: 17569103

Lu J, Risbood P, Kane CT Jr, Hossain MT, Anderson L, Hill K, Monks A, Wu Y, Antony S, Juhasz A, Liu H, Jiang G, Harris E, Roy K, Meitzler JL, Konaté M, Doroshow JH (2017) Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. Biochem Pharmacol 143:25–38. https://doi.org/10.1016/j.bcp.2017.07.007

doi: 10.1016/j.bcp.2017.07.007 pubmed: 28709950 pmcid: 5610936

Honore S, Kamath K, Braguer D, Wilson L, Briand C, Jordan MA (2003) Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol Cancer Ther 2(12):1303–1311

pubmed: 14707271

Gajula PK, Asthana J, Panda D, Chakraborty TK (2013) A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death. J Med Chem 56(6):2235–2245. https://doi.org/10.1021/jm3009629

doi: 10.1021/jm3009629 pubmed: 23445405

Bai R, Petit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39(12):1941–1949. https://doi.org/10.1016/0006-2952(90)90613-P

doi: 10.1016/0006-2952(90)90613-P pubmed: 2353935

Tomaszewski JE, Smith AC, Covey JM, Donohue SJ, Rhie JK, Schweikart KM (2002) Chapter 17 - Relevance of preclinical pharmacology and toxicology to phase i trial extrapolation techniques: relevance of animal toxicology. In: Baguley BC, Kerr DJ (eds) Anticancer drug development. Academic Press, San Diego, CA, pp 301–328. https://doi.org/10.1016/B978-012072651-6/50018-8

doi: 10.1016/B978-012072651-6/50018-8

Al-Hadiya BMH (2010) Chapter 5 - Parbendazole. In: Brittain HG (ed) Profiles of drug substances, excipients and related methodology, vol 35. Academic Press, New York, pp 263–284. https://doi.org/10.1016/S1871-5125(10)35005-9

doi: 10.1016/S1871-5125(10)35005-9

Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65(19):9047–9055. https://doi.org/10.1158/0008-5472.can-05-1235

doi: 10.1158/0008-5472.can-05-1235 pubmed: 16204079

Yonekura S, Itoh MAI, Okuhashi Y, Takahashi Y, Ono AYA, Nara N, Tohda S (2013) Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells. Anticancer Res 33(8):3099

pubmed: 23898065

Hajian R, Ekhlasi E, Daneshvar R (2012) Spectroscopic and Electrochemical Studies on the Interaction of Epirubicin with Fish Sperm DNA. E-J Chem 9(3):1587–1598. https://doi.org/10.1155/2012/738678

doi: 10.1155/2012/738678

Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325–2333

pubmed: 7757983

Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai Y-T, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC (2005) Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 105(1):350–357. https://doi.org/10.1182/blood-2004-06-2499

doi: 10.1182/blood-2004-06-2499 pubmed: 15367426

Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J (2011) Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 105(11):1646–1653. https://doi.org/10.1038/bjc.2011.438

doi: 10.1038/bjc.2011.438 pubmed: 22027708 pmcid: 3242596

Regueiro-Ren A, Borzilleri RM, Zheng X, Kim S-H, Johnson JA, Fairchild CR, Lee FYF, Long BH, Vite GD (2001) Synthesis and biological activity of novel epothilone aziridines. Org Lett 3(17):2693–2696. https://doi.org/10.1021/ol016273w

doi: 10.1021/ol016273w pubmed: 11506611

Molnar J, Somberg JC (2009) The clinical pharmacology of ethacrynic acid. Am J Ther 16(1):86–92. https://doi.org/10.1097/MJT.0b013e318195e460

doi: 10.1097/MJT.0b013e318195e460 pubmed: 19142159

Vigushin DM, Mirsaidi N, Brooke G, Sun C, Pace P, Inman L, Moody CJ, Coombes RC (2004) Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. Med Oncol 21(1):21–30. https://doi.org/10.1385/MO:21:1:21

doi: 10.1385/MO:21:1:21 pubmed: 15034210

Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY (2009) Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59(1):19–27. https://doi.org/10.1111/j.1440-1827.2008.02320.x

doi: 10.1111/j.1440-1827.2008.02320.x pubmed: 19121088

Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, Zhang J (2012) Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumor Biol 33(5):1349–1362. https://doi.org/10.1007/s13277-012-0383-6

doi: 10.1007/s13277-012-0383-6

Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID (2011) Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14(3):245–253. https://doi.org/10.1007/s10456-011-9209-1

doi: 10.1007/s10456-011-9209-1 pubmed: 21452059 pmcid: 3155047

Kurzrock R, Goel S, Wheler J, Hong D, Fu S, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Lokiec F, Mulcahy M (2012) Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118(24):6144–6151. https://doi.org/10.1002/cncr.27647

doi: 10.1002/cncr.27647 pubmed: 22674635

Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albæk C, Schrøder H, Ørum H (2008) A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7(11):3598–3608. https://doi.org/10.1158/1535-7163.mct-08-0510

doi: 10.1158/1535-7163.mct-08-0510 pubmed: 18974394

Krasieva TB, Ehren J, O’Sullivan T, Tromberg BJ, Maher P (2015) Cell and brain tissue imaging of the flavonoid fisetin using label-free two-photon microscopy. Neurochem Int 89:243–248. https://doi.org/10.1016/j.neuint.2015.08.003

doi: 10.1016/j.neuint.2015.08.003 pubmed: 26271433 pmcid: 4587296

Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP (2011) Fisetin inhibits various attributes of angiogenesis in vitro and in vivo —implications for angioprevention. Carcinogenesis 33(2):385–393. https://doi.org/10.1093/carcin/bgr282

doi: 10.1093/carcin/bgr282 pubmed: 22139440

Mie Lee Y, Kim S-H, Kim H-S, Jin Son M, Nakajima H, Jeong Kwon H, Kim K-W (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 300(1):241–246. https://doi.org/10.1016/S0006-291X(02)02787-0

doi: 10.1016/S0006-291X(02)02787-0 pubmed: 12480550

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66(17):8814–8821. https://doi.org/10.1158/0008-5472.can-05-4598

doi: 10.1158/0008-5472.can-05-4598 pubmed: 16951198

Kim KH, Jung HJ, Kwon HJ (2013) A new anti-angiogenic small molecule, G0811, inhibits angiogenesis via targeting hypoxia inducible factor (HIF)-1α signal transduction. Biochem Biophys Res Commun 441(2):399–404. https://doi.org/10.1016/j.bbrc.2013.10.075

doi: 10.1016/j.bbrc.2013.10.075 pubmed: 24161739

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11(2):475–484. https://doi.org/10.1158/1535-7163.mct-11-0755

doi: 10.1158/1535-7163.mct-11-0755 pubmed: 22144665

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI (2012) Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 18(18):4973–4985. https://doi.org/10.1158/1078-0432.ccr-11-2967

doi: 10.1158/1078-0432.ccr-11-2967 pubmed: 22806877 pmcid: 3477583

Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62(9):2478–2482

pubmed: 11980636

Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305–315. https://doi.org/10.1007/bf00689048

doi: 10.1007/bf00689048 pubmed: 7628050

Nagle DG, Zhou YD (2006) Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets 7(3):355–369

doi: 10.2174/138945006776054979 pubmed: 16515532 pmcid: 2908043

Huang T-S, Lee C-C, Chao Y, Shu C-H, Chen L-T, Chen L-L, Chen M-H, Yuan C-C, Whang-Peng J (1999) A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res 16(7):997–1002. https://doi.org/10.1023/A:1018971313256

doi: 10.1023/A:1018971313256 pubmed: 10450922

Lee S-H, Jee J-G, Bae J-S, Liu K-H, Lee YM (2015) A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and hsp90 binding. J Cell Physiol 230(4):853–862. https://doi.org/10.1002/jcp.24813

doi: 10.1002/jcp.24813 pubmed: 25204544

Simons R, Vincken J-P, Bohin MC, Kuijpers TFM, Verbruggen MA, Gruppen H (2011) Identification of prenylated pterocarpans and other isoflavonoids in Rhizopus spp. elicited soya bean seedlings by electrospray ionisation mass spectrometry. Rapid Commun Mass Spectrom 25(1):55–65. https://doi.org/10.1002/rcm.4826

doi: 10.1002/rcm.4826 pubmed: 21154654

Lee SH, Lee J, Jung MH, Lee YM (2013) Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways. Mol Nutr Food Res 57(2):225–234. https://doi.org/10.1002/mnfr.201200489

doi: 10.1002/mnfr.201200489 pubmed: 23229497

Blank M, Lavie G, Mandel M, Hazan S, Orenstein A, Meruelo D, Keisari Y (2004) Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer 111(4):596–603. https://doi.org/10.1002/ijc.20285

doi: 10.1002/ijc.20285 pubmed: 15239139

Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G (2003) Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res 63(23):8241–8247

pubmed: 14678981

Head CS, Luu Q, Sercarz J, Saxton R (2006) Photodynamic therapy and tumor imaging of hypericin-treated squamous cell carcinoma. World J Surg Oncol 4(1):87. https://doi.org/10.1186/1477-7819-4-87

doi: 10.1186/1477-7819-4-87 pubmed: 17147827 pmcid: 1762016

Jacobson JM, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, Cabana BE, Lee D-H, Spritzler J, Prince AM (2001) Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John’s Wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 45(2):517–524. https://doi.org/10.1128/aac.45.2.517-524.2001

doi: 10.1128/aac.45.2.517-524.2001 pubmed: 11158749 pmcid: 90321

Mirmalek SA, Azizi MA, Jangholi E, Yadollah-Damavandi S, Javidi MA, Parsa Y, Parsa T, Salimi-Tabatabaee SA, Ghasemzadeh Kolagar H, Alizadeh-Navaei R (2016) Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int 16(1):3. https://doi.org/10.1186/s12935-016-0279-4

doi: 10.1186/s12935-016-0279-4 pubmed: 26865836 pmcid: 4748624

Wang KS, Ma J, Mi C, Li J, Lee JJ, Jin X (2016) Kamebakaurin inhibits the expression of hypoxia-inducible factor-1alpha and its target genes to confer antitumor activity. Oncol Rep 35(4):2045–2052. https://doi.org/10.3892/or.2016.4576

doi: 10.3892/or.2016.4576 pubmed: 26781327

Xia Y, Feng M, Wang E, Chen L, Wang J, Hou R, Zhao Y (2019) An ent-Kaurane diterpenoid isolated from rabdosia excisa suppresses Bcr-Abl protein expression in vitro and in vivo and induces apoptosis of CML cells. Chem Biodivers 16(10):e1900443. https://doi.org/10.1002/cbdv.201900443

doi: 10.1002/cbdv.201900443 pubmed: 31468670

Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, Van Meir EG (2009) Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 15(19):6128–6136. https://doi.org/10.1158/1078-0432.ccr-08-3180

doi: 10.1158/1078-0432.ccr-08-3180 pubmed: 19789328 pmcid: 2770235

Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman MM, Nicolaou KC, Van Meir EG (2012) Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res 18(24):6623–6633. https://doi.org/10.1158/1078-0432.ccr-12-0861

doi: 10.1158/1078-0432.ccr-12-0861 pubmed: 22923450 pmcid: 3518680

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R (2012) KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One 7(9):e44883. https://doi.org/10.1371/journal.pone.0044883

doi: 10.1371/journal.pone.0044883 pubmed: 23028659 pmcid: 3441526

Kurebayashi J, Otsuki T, Kurosumi M, Soga S, Akinaga S, Sonoo H (2001) A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn J Cancer Res 92(12):1342–1351. https://doi.org/10.1111/j.1349-7006.2001.tb02159.x

doi: 10.1111/j.1349-7006.2001.tb02159.x pubmed: 11749701 pmcid: 5926684

Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96(6):2284–2291

doi: 10.1182/blood.V96.6.2284 pubmed: 10979978

Kwon HS, Kim D-R, Yang EG, Park YK, Ahn H-C, Min S-J, Ahn D-R (2012) Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1α–p300 interaction by a small molecule. Bioorg Med Chem Lett 22(16):5249–5252. https://doi.org/10.1016/j.bmcl.2012.06.054

doi: 10.1016/j.bmcl.2012.06.054 pubmed: 22789427

Brahmachari G (2013) Chemistry and pharmacology of naturally occurring bioactive compounds. CRC Press, Boca Raton, FL

doi: 10.1201/b13867

Yu M, Salvador LA, Sy SK, Tang Y, Singh RS, Chen QY, Liu Y, Hong J, Derendorf H, Luesch H (2014) Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs 12(3):1623–1640. https://doi.org/10.3390/md12031623

doi: 10.3390/md12031623 pubmed: 24658499 pmcid: 3967229

Xie SR, Wang Y, Liu CW, Luo K, Cai YQ (2012) Liquiritigenin inhibits serum-induced HIF-1alpha and VEGF expression via the AKT/mTOR-p70S6K signalling pathway in HeLa cells. Phytother Res 26(8):1133–1141. https://doi.org/10.1002/ptr.3696

doi: 10.1002/ptr.3696 pubmed: 22170854

Spencer JPE, Crozier RA (2016) Flavonoids and related compounds : bioavailability and function

Kong LD, Zhang Y, Pan X, Tan RX, CHK C (2000) Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Cell Mol Life Sci 57(3):500–505. https://doi.org/10.1007/PL00000710

doi: 10.1007/PL00000710 pubmed: 10823249

Lee K, Kang JE, Park S-K, Jin Y, Chung K-S, Kim H-M, Lee K, Kang MR, Lee MK, Song KB, Yang E-G, Lee J-J, Won M (2010) LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1α via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol 80(7):982–989. https://doi.org/10.1016/j.bcp.2010.06.018

doi: 10.1016/j.bcp.2010.06.018 pubmed: 20599784

Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241–5248

doi: 10.1016/S0021-9258(17)37680-9 pubmed: 8106507

Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Grønning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR (2007) Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 404(3):449–458. https://doi.org/10.1042/bj20070003

doi: 10.1042/bj20070003 pubmed: 17362206 pmcid: 1896275

Chen MC, Lee CF, Huang WH, Chou TC (2013) Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1alpha/VEGF signaling pathway in human bladder cancer cells. Biochem Pharmacol 85(9):1278–1287. https://doi.org/10.1016/j.bcp.2013.02.009

doi: 10.1016/j.bcp.2013.02.009 pubmed: 23416116

Ho JH-C, Hong C-Y (2012) Cardiovascular protection of magnolol: cell-type specificity and dose-related effects. J Biomed Sci 19(1):70. https://doi.org/10.1186/1423-0127-19-70

doi: 10.1186/1423-0127-19-70 pubmed: 22849814 pmcid: 3418199

He X, Zhang P, Saqib M, Wang S, Hou X (2017) Screening active anti-breast cancer compounds from Cortex Magnolia Officinalis by MCF-7 cell membrane chromatography coupled with UHPLC-ESI-MS/MS. Anal Methods 9(33):4828–4836. https://doi.org/10.1039/C7AY01213F

doi: 10.1039/C7AY01213F

Shin J-M, Jeong Y-J, Cho H-J, Park K-K, Chung I-K, Lee I-K, Kwak J-Y, Chang H-W, Kim C-H, Moon S-K, Kim W-J, Choi Y-H, Chang Y-C (2013) Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One 8(7):e69380. https://doi.org/10.1371/journal.pone.0069380

doi: 10.1371/journal.pone.0069380 pubmed: 23936001 pmcid: 3720276

Gribenko AV, Guzmán-Casado M, Lopez MM, Makhatadze GI (2002) Conformational and thermodynamic properties of peptide binding to the human S100P protein. Prot Sci 11(6):1367–1375. https://doi.org/10.1110/ps.0202202

doi: 10.1110/ps.0202202

Ridgway Z, Picciano AL, Gosavi PM, Moroz YS, Angevine CE, Chavis AE, Reiner JE, Korendovych IV, Caputo GA (2015) Functional characterization of a melittin analog containing a non-natural tryptophan analog. Biopolymers 104(4):384–394. https://doi.org/10.1002/bip.22624

doi: 10.1002/bip.22624 pubmed: 25670241 pmcid: 4516667

Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH (2009) Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 119(9):2830–2842. https://doi.org/10.1172/jci38842

doi: 10.1172/jci38842 pubmed: 19726870 pmcid: 2735896

Hu OY, Wu CY, Chan WK, Wu FY (1995) Determination of anticancer drug vitamin K3 in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 666(2):299–305. https://doi.org/10.1016/0378-4347(94)00572-M

doi: 10.1016/0378-4347(94)00572-M

Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J (2009) Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2(5):484–495. https://doi.org/10.1158/1940-6207.capr-08-0173

doi: 10.1158/1940-6207.capr-08-0173

Sinha I, Allen JE, Pinto JT, Sinha R (2014) Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia. Cancer Med 3(2):252–264. https://doi.org/10.1002/cam4.198

doi: 10.1002/cam4.198 pubmed: 24515947 pmcid: 3987075

Guo X, Yin S, Dong Y, Fan L, Ye M, Lu J, Hu H (2012) Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of mcl-1 and fak. Mol Carcinog 52(11):879–889. https://doi.org/10.1002/mc.21933

doi: 10.1002/mc.21933 pubmed: 22711297

Sinha I, Null K, Wolter W, Suckow MA, King T, Pinto JT, Sinha R (2012) Methylseleninic acid downregulates hypoxia-inducible factor-1alpha in invasive prostate cancer. Int J Cancer 130(6):1430–1439. https://doi.org/10.1002/ijc.26141

doi: 10.1002/ijc.26141 pubmed: 21500193

Tarrado-Castellarnau M, Cortés R, Zanuy M, Tarragó-Celada J, Polat IH, Hill R, Fan TWM, Link W, Cascante M (2015) Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition. Pharmacol Res 102:218–234. https://doi.org/10.1016/j.phrs.2015.09.009

doi: 10.1016/j.phrs.2015.09.009 pubmed: 26375988 pmcid: 4850087

Pautke C, Vogt S, Kreutzer K, Haczek C, Wexel G, Kolk A, Imhoff AB, Zitzelsberger H, Milz S, Tischer T (2010) Characterization of eight different tetracyclines: advances in fluorescence bone labeling. J Anat 217(1):76–82. https://doi.org/10.1111/j.1469-7580.2010.01237.x

doi: 10.1111/j.1469-7580.2010.01237.x pubmed: 20456523 pmcid: 2913014

Modheji M, Olapour S, Khodayar M, Jalili A, Yaghooti H (2016) Minocycline is more potent than tetracycline and doxycycline in inhibiting MMP-9 in vitro. Jundishapur J Nat Pharmac Prod. https://doi.org/10.17795/jjnpp-27377

Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM (2014) Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumor grafts. Int J Cancer 134(10):2322–2329. https://doi.org/10.1002/ijc.28579

doi: 10.1002/ijc.28579 pubmed: 24243565

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL (2016) TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: a phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström’s macroglobulinemia. Am J Hematol 91(4):400–405. https://doi.org/10.1002/ajh.24300

doi: 10.1002/ajh.24300 pubmed: 26800393

Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS (2009) mTOR mediated anti-cancer drug discovery. Drug Discov Today Therap Strat 6(2):47–55. https://doi.org/10.1016/j.ddstr.2009.12.001

doi: 10.1016/j.ddstr.2009.12.001

Slotkin EK, Patwardhan PP, Vasudeva SD, de Stanchina E, Tap WD, Schwartz GK (2014) MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther 14(2):395–406. https://doi.org/10.1158/1535-7163.mct-14-0711

doi: 10.1158/1535-7163.mct-14-0711 pubmed: 25519700 pmcid: 4332837

Siti MM, Yunos N, Jauri MH, Alias M, Krishnasamy G, Osman A, Norhayati I, Sahira L, Suryani S (2011) Potential anticancer compound from Cerbera odollam. J Trop For Sci 23:89–96

Wu D, Zhang R, Zhao R, Chen G, Cai Y, Jin J (2013) A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain. PLoS One 8(5):e62014. https://doi.org/10.1371/journal.pone.0062014

doi: 10.1371/journal.pone.0062014 pubmed: 23671581 pmcid: 3646014

Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC (1986) Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 30(1):42–45

doi: 10.1128/AAC.30.1.42 pubmed: 3752982 pmcid: 176432

Bendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JR (2015) A phase I study of the Hsp90 inhibitor AUY922 plus capecitabine for the treatment of patients with advanced solid tumors. Cancer Invest 33(10):477–482. https://doi.org/10.3109/07357907.2015.1069834

doi: 10.3109/07357907.2015.1069834 pubmed: 26460795

Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven BA, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8):2850–2860. https://doi.org/10.1158/0008-5472.can-07-5256

doi: 10.1158/0008-5472.can-07-5256 pubmed: 18413753

Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ (2011) Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 102(7):1388–1395. https://doi.org/10.1111/j.1349-7006.2011.01944.x

doi: 10.1111/j.1349-7006.2011.01944.x pubmed: 21453385

Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64(2):689–695. https://doi.org/10.1158/0008-5472.can-03-2043

doi: 10.1158/0008-5472.can-03-2043 pubmed: 14744786

de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14(20):6663–6673. https://doi.org/10.1158/1078-0432.ccr-08-0376

doi: 10.1158/1078-0432.ccr-08-0376 pubmed: 18927309

Burslem GM, Kyle HF, Breeze AL, Edwards TA, Nelson A, Warriner SL, Wilson AJ (2014) Small-molecule proteomimetic inhibitors of the hif-1α–p300 protein–protein interaction. Chem Bio Chem 15(8):1083–1087. https://doi.org/10.1002/cbic.201400009

doi: 10.1002/cbic.201400009 pubmed: 24782431

Qazzaz HMAM, El-Masri MA, Valdes JR (2000) Secretion of a lactone-hydrogenated ouabain-like effector of sodium, potassium-adenosine triphosphatase activity by adrenal cells. Endocrinology 141(9):3200–3209. https://doi.org/10.1210/endo.141.9.7664

doi: 10.1210/endo.141.9.7664 pubmed: 10965891

Cao J, He L, Lin G, Hu C, Dong R, Zhang J, Zhu H, Hu Y, Wagner CR, He Q, Yang B (2014) Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1alpha. Biochem Pharmacol 89(1):20–30. https://doi.org/10.1016/j.bcp.2013.12.002

doi: 10.1016/j.bcp.2013.12.002 pubmed: 24345331

Proppe D (1975) Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs. Clin Exp Pharmacol Physiol 2(6):489–502. https://doi.org/10.1111/j.1440-1681.1975.tb01854.x

doi: 10.1111/j.1440-1681.1975.tb01854.x pubmed: 1236603

Bloise E, Braca A, De Tommasi N, Belisario MA (2009) Pro-apoptotic and cytostatic activity of naturally occurring cardenolides. Cancer Chemother Pharmacol 64(4):793–802. https://doi.org/10.1007/s00280-009-0929-5

doi: 10.1007/s00280-009-0929-5 pubmed: 19184018

Yan K, Wang X, Jia Y, Chu Y, Guan X, Ma X, Li W, Pan G, Zhou S, Sun H, Liu C (2016) Quantitative determination of periplocymarin in rat plasma and tissue by LC-MS/MS: application to pharmacokinetic and tissue distribution study. Biomed Chromatogr 30(8):1195–1201. https://doi.org/10.1002/bmc.3667

doi: 10.1002/bmc.3667 pubmed: 26663385

Frölich JC, Falkner FC, Watson JT, Scheler F (1972) Metabolism of peruvoside in man. Eur J Clin Pharmacol 5(2):65–71. https://doi.org/10.1007/bf00561747

doi: 10.1007/bf00561747

Ji Y, Kuo Y, Morris ME (2005) Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res 22(10):1658–1666. https://doi.org/10.1007/s11095-005-7097-z

doi: 10.1007/s11095-005-7097-z pubmed: 16180123

Wang X-H, Cavell BE, Syed Alwi SS, Packham G (2009) Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. Biochem Pharmacol 78(3):261–272. https://doi.org/10.1016/j.bcp.2009.04.010

doi: 10.1016/j.bcp.2009.04.010 pubmed: 19376091

Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G (2003) The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2(3):235–243

pubmed: 12657718

Al-Temimay IA, AL-Jibouri MH, Hassan AA, Mohammad FI (2015) The optimum conditions for pleurotin production by Pleurotus spp. local isolates. Iraqi J Sci 56(3C):2542–2552

Denicolaï E, Baeza-Kallee N, Tchoghandjian A, Carré M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D (2014) Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget 5(21):10934–10948. https://doi.org/10.18632/oncotarget.2541

doi: 10.18632/oncotarget.2541 pubmed: 25400117 pmcid: 4279420

Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF (2007) Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 50(12):2767–2778. https://doi.org/10.1021/jm050752+

doi: 10.1021/jm050752+ pubmed: 17488003

Gallerne C, Prola A, Lemaire C (2013) Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta 1833(6):1356–1366. https://doi.org/10.1016/j.bbamcr.2013.02.014

doi: 10.1016/j.bbamcr.2013.02.014 pubmed: 23485394

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106(20):8368–8373. https://doi.org/10.1073/pnas.0903392106

doi: 10.1073/pnas.0903392106 pubmed: 19416831 pmcid: 2688867

Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S (2018) First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Invest New Drugs 36(2):230–239. https://doi.org/10.1007/s10637-017-0495-3

doi: 10.1007/s10637-017-0495-3 pubmed: 28808818

Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3(3):233–244

pubmed: 15026543

Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7(1):90–100. https://doi.org/10.1158/1535-7163.mct-07-0463

doi: 10.1158/1535-7163.mct-07-0463 pubmed: 18202012

Sharp SY, Prodromou C, Boxall K, Powers MV, Holmes JL, Box G, Matthews TP, Cheung K-MJ, Kalusa A, James K, Hayes A, Hardcastle A, Dymock B, Brough PA, Barril X, Cansfield JE, Wright L, Surgenor A, Foloppe N, Hubbard RE, Aherne W, Pearl L, Jones K, McDonald E, Raynaud F, Eccles S, Drysdale M, Workman P (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 6(4):1198–1211. https://doi.org/10.1158/1535-7163.mct-07-0149

doi: 10.1158/1535-7163.mct-07-0149 pubmed: 17431102

Yewalkar N, Deore V, Padgaonkar A, Manohar S, Sahu B, Kumar P, Jalota-Badhwar A, Joshi KS, Sharma S, Kumar S (2010) Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery. Bioorg Med Chem Lett 20(22):6426–6429. https://doi.org/10.1016/j.bmcl.2010.09.083

doi: 10.1016/j.bmcl.2010.09.083 pubmed: 20932758

Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Sonawane V, Rathos MJ, Kumar S, Joshi KS (2011) A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer 11:338–338. https://doi.org/10.1186/1471-2407-11-338

doi: 10.1186/1471-2407-11-338 pubmed: 21819554 pmcid: 3224262

T-b K, Liang N-c (1997) Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem Pharmacol 54(9):1013–1018. https://doi.org/10.1016/S0006-2952(97)00260-8

doi: 10.1016/S0006-2952(97)00260-8

de Paula RR, Tini IR, Soares CP, da Silva NS (2014) Effect of photodynamic therapy supplemented with quercetin in HEp-2 cells. Cell Biol Int 38(6):716–722. https://doi.org/10.1002/cbin.10251

doi: 10.1002/cbin.10251

Hur E, Kim H-H, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee M-O, Park H (2002) Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1α/Aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62(5):975–982. https://doi.org/10.1124/mol.62.5.975

doi: 10.1124/mol.62.5.975 pubmed: 12391259

Roe SM, Prodromou C, O’Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42(2):260–266. https://doi.org/10.1021/jm980403y

doi: 10.1021/jm980403y pubmed: 9925731

Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 22(20):7004–7014. https://doi.org/10.1128/MCB.22.20.7004-7014.2002

doi: 10.1128/MCB.22.20.7004-7014.2002 pubmed: 12242281 pmcid: 139825

Nalbandian A, Llewellyn KJ, Nguyen C, Yazdi PG, Kimonis VE (2015) Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy. PLoS One 10(4):e0122888. https://doi.org/10.1371/journal.pone.0122888

doi: 10.1371/journal.pone.0122888 pubmed: 25884947 pmcid: 4401571

Carter LG, D’Orazio JA, Pearson KJ (2014) Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 21(3):R209–R225. https://doi.org/10.1530/ERC-13-0171

doi: 10.1530/ERC-13-0171 pubmed: 24500760 pmcid: 4013237

Kim SH, Adhikari BB, Cruz S, Schramm MP, Vinson JA, Narayanaswami V (2015) Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing reconstituted HDL as a nanovehicle. PLoS One 10(8):e0135130. https://doi.org/10.1371/journal.pone.0135130

doi: 10.1371/journal.pone.0135130 pubmed: 26258481 pmcid: 4530947

Perrone D, Fuggetta MP, Ardito F, Cottarelli A, De Filippis A, Ravagnan G, De Maria S, Lo Muzio L (2017) Resveratrol (3,5,4′-trihydroxystilbene) and its properties in oral diseases. Exp Ther Med 14(1):3–9. https://doi.org/10.3892/etm.2017.4472

doi: 10.3892/etm.2017.4472 pubmed: 28672886 pmcid: 5488484

Tseng S-H, Lin S-M, Chen J-C, Su Y-H, Huang H-Y, Chen C-K, Lin P-Y, Chen Y (2004) Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 10(6):2190–2202. https://doi.org/10.1158/1078-0432.ccr-03-0105

doi: 10.1158/1078-0432.ccr-03-0105 pubmed: 15041740

Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(1):113–122. https://doi.org/10.1016/j.canlet.2005.01.031

doi: 10.1016/j.canlet.2005.01.031 pubmed: 16356836

Deng Y-T, Huang H-C, Lin J-K (2010) Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling. Mol Carcinog 49(2):141–151. https://doi.org/10.1002/mc.20583

doi: 10.1002/mc.20583 pubmed: 19777565

Han J-Y, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee H-Y (2005) Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. JNCI 97(17):1272–1286. https://doi.org/10.1093/jnci/dji251

doi: 10.1093/jnci/dji251 pubmed: 16145048

Awada A, Eskens FALM, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J (2002) Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38(17):2272–2278. https://doi.org/10.1016/S0959-8049(02)00379-9

doi: 10.1016/S0959-8049(02)00379-9 pubmed: 12441264

Dutta Gupta S, Revathi B, Mazaira GI, Galigniana MD, Subrahmanyam CVS, Gowrishankar NL, Raghavendra NM (2015) 2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: Rational identification of a new anticancer lead. Bioorg Chem 59:97–105. https://doi.org/10.1016/j.bioorg.2015.02.003

doi: 10.1016/j.bioorg.2015.02.003 pubmed: 25727264

Jo DH, An H, Chang D-J, Baek Y-Y, Cho CS, Jun HO, Park S-J, Kim JH, Lee H-Y, Kim K-W, Lee J, Park H-J, Kim Y-M, Suh Y-G, Kim JH (2014) Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors. J Mol Med 92(10):1083–1092. https://doi.org/10.1007/s00109-014-1168-8

doi: 10.1007/s00109-014-1168-8 pubmed: 24875598

Zhao J, Agarwal R (1999) Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 20(11):2101–2108. https://doi.org/10.1093/carcin/20.11.2101

doi: 10.1093/carcin/20.11.2101 pubmed: 10545412

Chabot GG (1997) Clinical Pharmacokinetics of Irinotecan. Clin Pharmacokinet 33(4):245–259. https://doi.org/10.2165/00003088-199733040-00001

doi: 10.2165/00003088-199733040-00001 pubmed: 9342501

Miller AA, Kurschel E, Osieka R, Schmidt CG (1987) Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23(9):1283–1287. https://doi.org/10.1016/0277-5379(87)90109-X

doi: 10.1016/0277-5379(87)90109-X pubmed: 3678322

Ghiaghi M, Forouzesh F, Rahimi H (2019) Effect of sodium butyrate on LHX1 mRNA expression as a transcription factor of HDAC8 in human colorectal cancer cell lines. Avicenna J Med Biotechnol 11(4):317–324

pubmed: 31908740 pmcid: 6925397

Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P (2006) Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 57(5):685–692. https://doi.org/10.1007/s00280-005-0068-6

doi: 10.1007/s00280-005-0068-6 pubmed: 16133532

Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99(7):1492–1498. https://doi.org/10.1111/j.1349-7006.2008.00837.x

doi: 10.1111/j.1349-7006.2008.00837.x pubmed: 18477034

Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai MH, Feng WC, Chow LP (2015) Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer. Mol Cell Proteom 14(6):1527–1545. https://doi.org/10.1074/mcp.M114.046417

doi: 10.1074/mcp.M114.046417

Strobach H, Wirth KE, Rojsathaporn K (1986) Absorption, metabolism and elimination of strophanthus glycosides in man. Naunyn Schmiedebergs Arch Pharmacol 334(4):496–500. https://doi.org/10.1007/bf00569392

doi: 10.1007/bf00569392 pubmed: 3821940

Li G, Shan C, Liu L, Zhou T, Zhou J, Hu X, Chen Y, Cui H, Gao N (2015) Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One 10(2):e0117440. https://doi.org/10.1371/journal.pone.0117440

doi: 10.1371/journal.pone.0117440 pubmed: 25659153 pmcid: 4320086

Li JF, Wei YX, Xu ZC, Dong C, Shuang SM (2004) Studies on the spectroscopic behavior of cryptotanshinone, tanshinone IIA, and tanshinone I. Spectrochim Acta A Mol Biomol Spectrosc 60(4):751–756. https://doi.org/10.1016/s1386-1425(03)00286-5

doi: 10.1016/s1386-1425(03)00286-5 pubmed: 15036084

Wang Y, Yan J, Li S, Cai X, Wang W, Luo K, Huang D, Gao J (2014) Pharmacokinetics and tissue distribution study of tanshinone IIA after oral administration of Bushen Huoxue Qubi granules to rats with blood stasis syndrome. Pharmaco Magaz 10(39):285–291. https://doi.org/10.4103/0973-1296.137369

doi: 10.4103/0973-1296.137369

Tsai M-Y, Yang R-C, Wu H-T, Pang J-HS, Huang S-T (2011) Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer Lett 310(2):198–206. https://doi.org/10.1016/j.canlet.2011.06.031

doi: 10.1016/j.canlet.2011.06.031 pubmed: 21788102

Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J, Wang W (2005) Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116(5):799–807. https://doi.org/10.1002/ijc.20880

doi: 10.1002/ijc.20880 pubmed: 15849732

Su C-C, Lin Y-H (2008) Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 22(3):357–361. https://doi.org/10.3892/ijmm_00000030

doi: 10.3892/ijmm_00000030 pubmed: 18698495

Gong Y, Li Y, Abdolmaleky HM, Li L, Zhou JR (2012) Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One 7(4):e33656. https://doi.org/10.1371/journal.pone.0033656

doi: 10.1371/journal.pone.0033656 pubmed: 22485147 pmcid: 3317444

Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK, Eccles SA, Tavassoli A (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc 135(28):10418–10425. https://doi.org/10.1021/ja402993u

doi: 10.1021/ja402993u pubmed: 23796364 pmcid: 3715890

Nishikawa T, Takaoka M, Ohara T, Tomono Y, Hao H, Bao X, Fukazawa T, Wang Z, Sakurama K, Fujiwara Y, Motoki T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y (2013) Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. Cancer Biol Ther 14(3):230–236. https://doi.org/10.4161/cbt.23294

doi: 10.4161/cbt.23294 pubmed: 23291985 pmcid: 3595305

Merritt WM, Danes CG, Shahzad MMK, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596–1603. https://doi.org/10.4161/cbt.8.16.9004

doi: 10.4161/cbt.8.16.9004 pubmed: 19738426 pmcid: 3916970

Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845–6848. https://doi.org/10.1158/0008-5472.can-04-2116

doi: 10.1158/0008-5472.can-04-2116 pubmed: 15466170

Burke TG, Malak H, Gryczynski I, Mi Z, Lakowicz JR (1996) Fluorescence detection of the anticancer drug topotecan in plasma and whole blood by two-photon excitation. Anal Biochem 242(2):266–270. https://doi.org/10.1006/abio.1996.0463

doi: 10.1006/abio.1996.0463 pubmed: 8937572 pmcid: 6915068

Caceres G, Zankina R, Zhu X, Jiao JA, Wong H, Aller A, Andreotti P (2003) Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. Anticancer Drugs 14(7):569–574. https://doi.org/10.1097/00001813-200308000-00010

doi: 10.1097/00001813-200308000-00010 pubmed: 12960742

Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32(10):1132–1138. https://doi.org/10.1124/dmd.104.000638

doi: 10.1124/dmd.104.000638 pubmed: 15269190

Song X, Yao J, Wang F, Zhou M, Zhou Y, Wang H, Wei L, Zhao L, Li Z, Lu N, Guo Q (2013) Wogonin inhibits tumor angiogenesis via degradation of HIF-1alpha protein. Toxicol Appl Pharmacol 271(2):144–155. https://doi.org/10.1016/j.taap.2013.04.031

doi: 10.1016/j.taap.2013.04.031 pubmed: 23707765

Talbi A, Zhao D, Liu Q, Li J, Fan A, Yang W, Han X, Chen X (2014) Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats. Molecules (Basel, Switzerland) 19(5):5538–5549. https://doi.org/10.3390/molecules19055538

doi: 10.3390/molecules19055538

Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L (2007) Covalent reactions of wortmannin under physiological conditions. Chem Biol 14(3):321–328. https://doi.org/10.1016/j.chembiol.2007.02.007

doi: 10.1016/j.chembiol.2007.02.007 pubmed: 17379147

Yeo EJ, Ryu JH, Chun YS, Cho YS, Jang IJ, Cho H, Kim J, Kim MS, Park JW (2006) YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 66(12):6345–6352. https://doi.org/10.1158/0008-5472.can-05-4460

doi: 10.1158/0008-5472.can-05-4460 pubmed: 16778212

Yeo E-J, Chun Y-S, Cho Y-S, Kim J, Lee J-C, Kim M-S, Park J-W (2003) YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. JNCI 95(7):516–525. https://doi.org/10.1093/jnci/95.7.516

doi: 10.1093/jnci/95.7.516 pubmed: 12671019

Xu Z, Zhao J, Gou S, Xu G (2017) Novel hypoxia-targeting Pt(IV) prodrugs. Chem Commun 53(26):3749–3752. https://doi.org/10.1039/C7CC01320E

doi: 10.1039/C7CC01320E

Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Mark J de Keijzer (MJ)

Daniel J de Klerk (DJ)

Lianne R de Haan (LR)

Robert T van Kooten (RT)

Leonardo P Franchi (LP)

Lionel M Dias (LM)

Tony G Kleijn (TG)

Diederick J van Doorn (DJ)

Michal Heger (M)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH